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ABSTRACT 
Fe65 interacts with the cytosolic domain of the Alzheimer’s amyloid precursor protein 
(APP). The functions of the Fe65 and of the Fe65/APP complex are still unknown. To 
address this point we generated Fe65 knock out mice. These mice do not show any obvious 
phenotype, however, when fibroblasts (MEFs), isolated form Fe65 KO embryos, were 
exposed to low doses of DNA damaging agents, such as etoposide or H2O2, an increased 
sensitivity to genotoxic stress, compared to wild type animals, clearly emerged. 
Accordingly, brain extracts from Fe65 KO mice, exposed to non-lethal doses of ionizing 
radiations, showed high levels of γ-H2AX and p53, thus demonstrating a higher sensitivity 
to X-rays than wild type mice. Nuclear Fe65 is necessary to rescue the observed phenotype 
and, few minutes after the exposure of MEFs to DNA damaging agents, Fe65 undergoes 
phosphorylation in the nucleus. With a similar timing, the proteolytic processing of APP is 
rapidly affected by the genotoxic stress: in fact, the cleavage of the APP C-terminal 
fragments by γ-secretase is induced soon after the exposure of cells to etoposide, in a Fe65-
dependent manner. These results demonstrate that Fe65 plays an essential role in the 
response of the cells to DNA damage. Moreover we found that Fe65 is a chromatin bound 
protein that determines the degree of chromatin condensation both in basal and under 
genotoxic stress conditions. Fe65 association with chromatin is required during DNA 
damage repair. Indeed a known partner of Fe65 is the histone acetyltransferase Tip60. 
Considering the crucial role of Tip60 in DNA repair, we explored the hypothesis that the 
phenotype of Fe65 null cells was dependent on its interaction with Tip60. We 
demonstrated that Fe65 knockdown impaired recruitment of Tip60-TRRAP complex to 
DNA double strand breaks and decreased histone H4 acetylation. Accordingly, the 
efficiency of DNA repair was decreased upon Fe65 suppression. To explore whether APP 
has a role in this mechanism, we analyzed a Fe65 mutant unable to bind to APP. This 
mutant failed to rescue the phenotypes of Fe65 null cells; furthermore, APP/APLP2 
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suppression results in the impairment of recruitment of Tip60-TRRAP complex to DNA 
double strand breaks, decreased histone H4 acetylation and repair efficiency. On these 
bases, we propose that Fe65 and its interaction with APP play an important role in the 


























1. Familial and sporadic Alzheimer’s disease 
A century ago, Alois Alzheimer first described the neurological disease that bears his 
name. He described typical clinical characteristics with memory disturbances and 
instrumental signs, and he detailed two characteristic pathological features that are 
observed post mortem: amyloid plaques, and neurofibrillary tangles in the cerebral cortex 
and limbic system, which we today know as the hallmarks of the disease. Alzheimer’s 
disease (AD) is a slowly progressive disorder, with insidious onset and progressive decline 
in cognitive and functional abilities as well as behavioral and psychiatric symptoms 
leading to a vegetative state and ultimately death. AD is the most common cause of 
dementia, accounting for 50–60% of all cases (Moller and Graeber 1998). The prevalence 
of dementia is below 1% in individuals aged 60–64 years, but shows an almost exponential 
increase with age, so that in people aged 85 years or older the prevalence is between 24% 
and 33% in the Wester world. AD is very common and thus it is a major public health 
problem. In 2001, more than 24 million people had dementia, a number that is expected to 
double every 20 years up to 81 million in 2040 because of the anticipated increase in life 
expectancy (Ferri, Prince et al. 2005). Besides ageing, which is the most obvious risk 
factor for the disease, epidemiological studies have suggested several tentative 
associations. Some can be linked to brain trauma (Jellinger 2004), vascular diseases 
(Mayeux 2003), dietary life style (Luchsinger and Mayeux 2004), but data so far are not 
conclusive. Although environmental factors might increase the risk of sporadic AD, this 
form of the disease has been shown to have a significant genetic background. A large 
population based twin study showed that the extent of heritability for the sporadic disease 
is almost 80% (Gatz, Reynolds et al. 2006). Alzheimer’s disease is a heterogeneous 
disorder with both familial and sporadic forms. Familial AD is an autosomal dominant 
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disorder with onset before age 65 years. Four genes have been unequivocally implicated in 
inherited forms of AD and mutations or polymorphisms in these genes cause excessive 
cerebral accumulation of the amyloid ß-protein and subsequent neuronal and glial 
pathology in brain regions important for memory and cognition. The first mutation causing 
the familial form of the disease was identified in the amyloid precursor protein (APP) gene 
on chromosome 21 (St George-Hyslop, Haines et al. 1990). In 1988, the APP gene was 
found to reside on chromosome 21, which is triplicated in Down syndrome (trisomy 21). 
Indeed, most Down syndrome patients manifest Alzheimer disease (AD) by the age of 50, 
and post-mortem analyses of those who die young show diffuse intraneuronal deposits of 
Aβ in the absence of any tau pathology, suggesting that Aβ deposition is an early event in 
AD. When investigating other families with the familial disease, several additional APP 
mutations were found. The recent discovery of an extra copy of the APP gene in familial 
AD (Rovelet-Lecrux, Hannequin et al. 2006) provides further support that increased Aβ 
production can cause the disease. However, these mutations explain only a few familial 
cases. Indeed in 1995 mutations in the highly homologous presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2) genes were also linked with early-onset familial AD (Levy-Lahad, 
Lahad et al. 1995) (Rogaev, Sherrington et al. 1995) and they account for most cases of 
familial disease. However, the familial form of the disease is rare, with a prevalence below 
0.1%. In 1993, two groups independently reported an association between the 
apolipoprotein E (APOE) ε4 allele and AD (Poirier, Davignon et al. 1993). Meta-analysis 
showed that the APOE ε4 allele increases the risk of the disease by three times in 
heterozygotes and by 15 times in homozygotes (Dickson, Saunders et al. 1997). The 
mechanism underlying this increased risk is not completely clear, yet mounting evidence 
supports the idea that the ability of apoE to interact with the amyloid-β peptide and 
influence its conformation and clearance plays a major role. In vivo, it has been shown that 
breeding of APP-overexpressing mice with apoE knockout mice completely abolishes 
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amyloid plaque deposition in the brain of hybrid animals, confirming that apoE favours the 
extracellular β-amyloid deposition impairing through still unknown mechanisms the β-
amyloid clearance. Other susceptibility loci have been identified, but the data so far are 
unclear. 
 
2. Pathological features of Alzheimer disease 
At the microscopic level, the characteristic lesions in Alzheimer’s disease are senile or 
neuritic plaques and neurofibrillary tangles (Figure 1) in the medial temporal lobe 
structures and cortical areas of the brain, together with a degeneration of the neurons and 
synapses. These histological lesions can be observed as neuritic plaques or diffuse plaques. 
Neuritic plaques are microscopic foci of extracellular amyloid deposition and associated 
axonal and dendritic injury. The plaques are composed primarily of the 39–43-residue 
amyloid β-peptide (Aβ) (Wolfe 2006). Aβ is released from the amyloid precursor protein 
(APP) by the sequential action of β- and γ-secretases, with the latter cutting relatively 
heterogeneously (Esler and Wolfe 2001). Most of the Aβ produced by γ-secretase is the 
40-residue form (Aβ40); however, the major Aβ species deposited in the plaques is the 42-
residue variant (Aβ42), although this peptide represents only 5–10% of all Aβ produced. 
Such plaques contain extracellular deposits of amyloid β-protein (Aβ) that occur 
principally in a filamentous form, i.e., as star-shaped masses of Amyloid fibrils. 
Dystrophic neurites occur both within this amyloid deposit and immediately surrounding it 
(Poirier 2003). Such plaques are also intimately associated with microglia expressing 
surface antigens associated with activation, such as CD45 and HLA-DR, and they are 
surrounded by reactive astrocytes displaying abundant glial filaments. Diffuse plaques 
show a finely granular pattern, without a clearly fibrillar, compacted center associated with 
little or not detectable neuritic dystrophy. It has been suggested that these plaques might 
represent precursor lesions of neuritic plaques. 
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Plaques are extracellular deposits of Aβ surrounded by dystrophic neurites, reactive 
astrocytes, and microglia, whereas tangles are intracellular aggregates composed of a 







The hypothesis that diffuse plaques represent immature lesions that are precursors to the 
plaques with surrounding cytopathology arose from two lines of evidence. First, diffuse 
plaques are the sole form found in the brain regions that largely or entirely lacked neuritic 
dystrophy, glial changes, and neurofibrillary tangles and are not clearly implicated in the 
typical clinical symptoms of AD, e.g.,cerebellum, striatum, and thalamus. Second, healthy 
aged individuals free of AD or other dementing processes often show solely diffuse 
plaques in limbic and association cortices, i.e., in the same regions where Alzheimer 
patients show mixtures of diffuse and neuritic plaques. 
Neurofibrillary tangles are large, non membrane bound bundles of abnormal fibers that 
accumulate in the perinuclear region of cytoplasm. Electron microscopy reveals that most 
of these fibers consist of pairs of 10-nm filaments wound into helices (paired helical 
filaments or PHF), composed of the microtubule-associated protein tau (Brion, Couck et al. 
1985)  (Kosik, Joachim et al. 1986) (Nukina and Ihara 1986) (Wood, Mirra et al. 1986), 
which is present in a hyperphosphorylated form. A variety of kinases have been shown to 
be capable of phosphorylating tau in vitro at various sites (Illenberger, Zheng-Fischhofer et 
al. 1998), that leads to its apparent dissociation from microtubules and aggregation into 
insoluble paired helical filaments. The two classical lesions of AD, neuritic plaques and 
neurofibrillary tangles, can occur independently of each other. Tangles composed of tau 
aggregates that are biochemically similar to or, in some cases, indistinguishable from those 
in AD have been described in more than a dozen of less common neurodegenerative 
diseases, in almost all of which no Aβ deposits and neuritic plaques are present. 
Conversely, Aβ deposits can be seen in the brains of cognitively normal-aged humans in 
the virtual absence of tangles (Terry, Hansen et al. 1987). 
Genetic and pathological evidence strongly supports the amyloid cascade hypothesis of 
AD, which states that amyloid-β42, the proteolytic derivative of APP, has an early and 
vital role in all cases of AD. Indeed APP mutations associated with early-onset dominant 
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AD are located in and around the Aβ region of the encoded type I integral membrane 
glycoprotein. These mutations were soon determined to alter the amount of Aβ produced, 
the ratio of Aβ42 to Aβ40 or the amino-acid sequence of Aβ (Selkoe and Kopan 2003). 
Mutations near the β-secretase cleavage site make APP a better substrate for this enzyme 
and lead to increased production of all forms of Aβ. Mutations near the γ-secretase 
cleavage site lead to increases in the more aggregation-prone Aβ42 relative to Aβ40, and 
mutations in the Aβ region itself change the biophysical properties of the peptide to render 
it more likely to aggregate. These findings provided the first compelling evidence that Aβ 
might be involved in the pathogenesis of AD rather than simply being a marker. Moreover, 
the AD-associated mutations of PS1 and PS2 genes, were soon determined to increase the 
ratio of Aβ42 to Aβ40 (Aβ42/Aβ40) in mice and humans (Borchelt, Thinakaran et al. 
1996) (Citron, Oltersdorf et al. 1992) (Scheuner, Eckman et al. 1996), indicating that 
presenilins might modify the way in which γ-secretase cuts APP. 
 
 
3. APP proteolitic processing : focusing on γ-secretase complex activity 
The purification and partial sequencing of the Aβ protein from meningovascular amyloid 
deposits in AD led to the cloning of the gene encoding the β-APP (Kang, Lemaire et al. 
1987). Aβ is derived from its large precursor protein by sequential proteolytic cleavages. 
APP is an integral membrane protein with a single membrane spanning domain, a large 
extracellular glycosylated N-terminus and a shorter cytoplasmic C-terminus. Aβ is located 
at the cell surface (or on the lumenal side of ER and Golgi membranes), with part of the 
peptide embedded in the membrane. APP (Kang et al. 1987) (Goldgaber, Lerman et al. 
1987) is a member of an evolutionarily conserved family of type I membrane proteins. 
Mammals have two APP-like paralogues, APLP-1 and APLP-2 (Wasco, Bupp et al. 1992), 
which have substantial homology, both within the large ectodomain and particularly within 
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the cytoplasmic tail, but are largely divergent in the Aβ region. The evolutionary 
conservation of the APP gene family also extends to invertebrates, with the Drosophila 
gene product known as APPL and the Caenorhabditis elegans homologue named APL-1. 
APP comprises a heterogeneous group of ubiquitously expressed polypeptides derived 
from alternatively spliced isoforms, yielding 3 isoforms of 695, 751, and 770 residues. The 
most abundant form in brain is APP695, that is produced mainly by neurons, and differs 
from longer forms of APP in that it lacks a kunitz type protease inhibitor sequence in its 
ectodomain (Hardy and Hutton 1995).  
Both during and after its trafficking through the secretory pathway to the cell surface, a 
subset of APP molecules undergoes specific endoproteolytic cleavages to release secreted 
derivatives into vesicle lumens and the extracellular space (Figure 2). Enzyme activities 
involved in cleavage of APP at the α-, β- and γ-secretase sites are being identified 
(Annaert, Levesque et al. 1999). The majority of APP is cleaved by α-secretases within the 
Aβ sequence thus precluding Aβ generation (Ikezu, Trapp et al. 1998). The identity of α-
secretase remains unclear, although metalloproteases as TACE (an enzyme responsible for 
cleavage of members of the TNF receptor family at the cell surface) and ADAM9 and 
ADAM10 are candidates (Hutton, Lendon et al. 1998; Illenberger, Zheng-Fischhofer et al. 
1998). This cleavage results in the release of soluble sAPPα and retention of a C83 
fragment in the membrane. Cleavage of C83 by γ-secretase results in release of a p3 
fragment (approximately 3 kDa) and γ-cleaved C-terminal fragments (γCTF) also known 
as the APP intracellular domain (AICD). Amyloidogenic processing of APP involves 
sequential cleavages by BACE and γ-secretase at the N- and C-termini of Aβ, respectively. 
Cleavage of C99 by γ-secretase generates the AICD and Aβ peptides including Aβ40 and 
the more amyloidogenic Aβ42 (Selkoe 2001). The concept that missense mutations in APP 
cause AD via an amyloidogenic mechanism is strongly supported by the fact that all of the 
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APP is a transmembrane protein with a large N-terminal extracellular domain and a short 
cytosolic tail. In the α-secretase pathway, α secretase cleaves APP within the Aβ domain, 
releasing the large soluble APP fragment (α-sAPP). The remaining C-terminal fragment 
(CTF), C83, is cleaved by the γ-secretase releasing the short p3 peptide. The remaining 
APP intracellular domain (AICD) is metabolised in the cytoplasm. In the β-secretase 
pathway, β-secretase cleaves APP upstream of the Aβ domain, releasing soluble βsAPP. 
The remaining CTF, C99, is cleaved by the γ-secretase releasing the free 40 or 42 
aminoacid Aβ peptide. Two further cleavage sites of the γ-secretase, termed ε and ζ, are 
present in the CTF. The remaining AICD is metabolised in the cytoplasm. (Figure 
modified from Sastre et al. Journal of Neuroinflammation 2008 5:25) 
 
 14
known mutations occur within the region encoded by Aβ or immediately adjacent to β-and 
γ-secretase cleavage sites (Hardy 1997). Indeed, these mutations alter either the properties 
of Aβ or how much and what type of Aβ is produced. The “Swedish” double mutation 
found at the P2 and P1 sites for ß-secretase causes more efficient processing of APP by this 
aspartyl protease, resulting in a several-fold increase in the production of both Aß40 and 
Aß42 (Citron, Oltersdorf et al. 1992). On the other hand, the several mutations located C-
terminal to the γ -secretase site increase the ratio of peptides ending at Aß42 to those 
ending at Aß40 (De Jonghe, Esselens et al. 2001) (Suzuki, Cheung et al. 1994) (Scheuner, 
Eckman et al. 1996). Because the hydrophobic Aß42 peptide is more prone to self-
assembly (Jarrett, Berger et al. 1993), increases in its relative amount can promote the 
formation of oligomeric intermediates and, eventually, mature amyloid fibrils. Among the 
mutations associated with prominent microvascular deposition, the E22Q (“Dutch”) 
peptide aggregates on the surfaces of smooth muscle and endothelial cells and thus confers 
local toxicity that could lead to necrosis and vessel rupture (Eisenhauer, Johnson et al. 
2000) (Van Nostrand, Melchor et al. 2001) (Wang, Natte et al. 2000). Another major clue 
to Alzheimer pathogenesis involving APP proteolitic processing, came with the discovery 
of two related genes, presenilin-1 (PS1) and presenilin-2 (PS2), likewise associated with 
early-onset disease (Sherrington, Rogaev et al. 1995) (Levy-Lahad, Wasco et al. 1995) 
(Rogaev, Sherrington et al. 1995). PS1 mutations cause the earliest and most-aggressive 
form of AD, commonly leading to onset of symptoms in the fifth decade of life and demise 
of the patient in the sixth. PS2 mutations generally have a slightly later and more-variable 
age of onset. More than 100 such missense mutations have been identified so far and the 
vast majority of those examined in detail skew the proportion of Aβ toward the more 
aggregation-prone 42-residue form (Tanzi and Bertram 2005). Thus, the presenilin 
mutations change the cleavage site specificity of γ-secretase. The knockout of PS1 in mice 
was found to markedly reduce γ-secretase cleavage of APP , and follow-up studies showed 
 15
 16
that the knockout of both PS1 and PS2 eliminated γ-secretase cleavage completely 
(Herreman, Serneels et al. 2000) (Zhang, Goodyer et al. 2000). Presenilins are therefore 
essential for this proteolytic function. Parallel studies revealed that peptide-substrate 
mimics with classical aspartyl protease-inhibitory motifs could inhibit γ-secretase, 
suggesting that the enzyme belongs to this category of proteases (Wolfe, De Los Angeles 
et al. 1999). This led to the identification of two conserved transmembrane aspartates in 
presenilin that are essential for γ-secretase activity, and the idea that presenilin is the 
catalytic component of the enzyme (Wolfe, Xia et al. 1999). 
Presenilin mutations occur in the catalytic subunit of the protease responsible for 
determining the length of Aβ peptides. Presenilin also has non-proteolytic functions (Baki, 
Shioi et al. 2004) (Huppert, Ilagan et al. 2005), the disruption of which might also 
contribute to familial AD pathogenesis. However, presenilin and γ-secretase have other 
substrates besides APP. After interacting with its cognate ligands, the Notch receptor 
undergoes a series of proteolytic events, in a manner similar to APP, ultimately releasing 
the intracellular domain that mediates the expression of genes controlling many types of 
cellular differentiation. We now know that the same γ-secretase cuts the transmembrane 
domain of the APP and Notch families of proteins, as well as a long list of other type I 
integral membrane proteins, including neuregulin and its receptor ErbB4, E-cadherins and 
N-cadherins, CD44, LDL-receptorrelated protein (LRP), nectin-1 and growth hormone 
receptor. 
Cleavage of some of these substrates apparently has a role in cell signalling, but other 
cleavage events might simply be a means of clearing out membrane-bound stubs after 
ectodomain shedding (Schroeter, Ilagan et al. 2003). In parallel with the discovery of 
presenilin as a protease that cleaves APP and Notch, AD-causing mutations in presenilin 
were found to have reduced proteolytic function. Yankner and colleagues first showed this 
effect with a range of mutant presenilins by using a Notch-based luciferase-reporter assay 
(Song, Nadeau et al. 1999). Several other groups have since noted this phenomenon; for 
example, De Strooper and colleagues showed that mutations in presenilin reduced its 
proteolytic function towards several different substrates (Bentahir, Nyabi et al. 2006). 
These findings raise an apparent paradox, in which AD-causing disease mutations cause 
both a ‘gain of function’, an increase in Aβ42/Aβ40, and a ‘loss of function’, a decrease in 
proteolytic activity. These seemingly opposing effects have elicited considerable debate 
over how the presenilin mutations cause AD, with some researchers suggesting that 
reducing Aβ production with candidate therapeutics might even exacerbate or even cause 
the disease. To appreciate the resolution of this purported paradox, it should initially be 
noted that the presenilin-containing γ-secretase complex cuts the transmembrane domain of 
APP, and other substrates, in at least two positions: the γ-site that produces the carboxyl 
terminus of Aβ and the ε-site further downstream that produces the amino terminus of the 
APP intracellular domain (AICD) (Figure3) (Evin and Weidemann 2002). Cleavage at the 
γ-site is heterogeneous, producing Aβ peptides of 39–43 residues, whereas the cut at the ε-
site produces almost exclusively a 50-residue AICD. The same phenomenon occurs with 
Notch, involving heterogeneous cleavage in the middle of the transmembrane domain (the 
S4 site) and homogeneous cleavage further downstream (at the S3 site); (Fluhrer, 
Multhaup et al. 2003). Interestingly, proteolysis at these two sites is affected by AD-
causing mutations in APP and the presenilins, which lead to an increase in the proportion 
of Aβ42 relative to Aβ40 along with an increase in a new 51-residue AICD relative to the 
50-residue product (Sato, Dohmae et al. 2003). These two proteolytic events are therefore 
not completely independent: a change in the cleavage site in one correlates with a change 
in the cleavage site of the other. Recent evidence from Ihara and colleagues indicates that 
the ε-cleavage might occur before proteolysis at the γ-site. Indeed, analysis of intracellular 
Aβ reveals a small but significant amount of longer forms of this peptide, up to Aβ49, 
which is the proteolytic counterpart to the 50-residue AICD 
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This model of processive proteolysis of the amyloid precursor protein transmembrane 
domain by γ-secretase, beginning at the ε-cleavage site and cleaving every three residues 
explains how reduction of proteolytic function due to presenilin mutations might lower 
amyloid β-peptide (Aβ) production but increase the ratio of Aβ42 to Aβ40. Longer forms 
of Aβ, including most of the hydrophobic transmembrane domain, might be more likely to 
be retained in the active site of the protease,whereas the shorter forms are more likely to be 
released. Less catalytically efficient γ-secretase complexes would allow more time for the 
release of longer Aβ peptides. In addition, Alzheimer disease-causing presenilin mutations 
shift the initial ε-cleavage site to produce more Aβ48, which would lead to Aβ42. (Figure 




(Qi-Takahara, Morishima-Kawashima et al. 2005); by contrast, longer AICDs, for example 
AICD counterparts to Aβ40 or Aβ42, have not been detected. Moreover, expression of 
Aβ49 leads to the secretion of Aβ40 and Aβ42 in the same proportion that is produced by 
γ-secretase (Funamoto, Morishima-Kawashima et al. 2004). Swapping tryptophan residues 
into the γ-site within the APP transmembrane domain prevents γ-cleavage but allows ε-
cleavage; however, swapping tryptophans into the ε-site leads to proteolysis between the γ-
site and ε-site, at a so-called ζ-site (Sato, Tanimura et al. 2005). Installing tryptophans into 
the ζ-site prevents any transmembrane cleavage of APP. Therefore, with these tryptophan 
swaps, ε-cleavage can occur without γ-cleavage, but γ-cleavage is not seen without ε-
cleavage or ζ-cleavage. Interestingly, longer Aβ peptides resulting from cleavage at the ζ-
site are seen intracellularly on treatment with one particular γ-secretase inhibitor: a 
dipeptide analogue called DAPT (Yagishita, Morishima-Kawashima et al. 2006). Finally, a 
mutation in PS1, M233T, leads to alternative ε-cleavage, producing the 51-residue AICD 
and its counterpart Aβ48 in a cell-free assay with detergent-solubilized membranes 
(Kakuda, Funamoto et al. 2006). 
One way to explain two major cleavage sites would be the presence of two pairs of 
catalytic aspartates within a presenilin dimer at the core of the γ-secretase complex. Initial  
proteolysis at the ε-site leads to the release of AICD, but the long Aβ products (Aβ49 or 
Aβ48) remain in the active site, and are successively cleaved every three residues upstream 
at the ζ-sites and then again at the γ-sites (Qi-Takahara, Morishima-Kawashima et al. 
2005). Specifically, they propose that Aβ49 is processed to Aβ46, Aβ43 and Aβ40, 
whereas Aβ48 is trimmed to Aβ45, Aβ42 and Aβ39. This model of processing proteolysis 
from the ε-site to the γ-sites elegantly explains how so many presenilin mutations can both 
reduce proteolytic activity causing a loss of function, and increase the Aβ42/Aβ40 ratio, 
causing a gain of function. Mutant versions of the enzyme that are less proteolytically 
efficient also cut proportionately more at the alternative ε-site, producing Aβ48 (Sato et al, 
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2003). The slower mutant enzymes allow proportionately more release of Aβ42 before 
further trimming to Aβ39. The net result might be less total Aβ, including less Aβ40 
(Bentahir, Nyabi et al. 2006), but the ratio of Aβ42 to Aβ40 is elevated. This proposed 
mechanism for γ-seretase activity could explain how the reduction of enzymatic activity 
results in increased Aβ42/Aβ40, but on the other hand it should be taken in account that 
gentation of AICD counterpart could be affected. Indeed the very aggressive FAD 
mutation L166P not only induces an exceptionally high increase of Abeta(42) production 
but also impairs NICD production and Notch signaling, as well as AICD generation 
probably leading to the loss of an intracellular still unknown function (Moehlmann, 
Winkler et al. 2002). 
This same mechanism might also account for the changes in Aβ42/Aβ40 seen with 
Alzheimer-causing APP mutations that are located near the γ-secretase cleavage sites; in 
these cases, the mutant substrates might be processed less efficiently by the wild-type 
protease. The scenario described above, which is supported by numerous reports, also 
provides an explanation for why the deletion of three out of four presenilin alleles in mice 
with only one PS1 allele remaining does not result in elevated Aβ42/Aβ40 (Lai, Chen et al. 
2003)  (Refolo, Eckman et al. 1999): the remaining γ-secretase complexes are wild type, 
have normal proteolytic activity and trim ε-cleaved Aβ efficiently. This is also consistent 
with the fact that although more than 100 missense mutations in PS1 and PS2 have so far 
been associated with AD, none are complete loss-of-function mutations in an allele, for 
example, complete deletion, loss of expression, mutation of one of the catalytic aspartates 
or severe truncations. The overexpression of presenilins does not result in increased 
activity of γ-secretase activity suggesting the presence of possible limiting factors 
participating to the catalytic activity. Indded the γ-secretase activity, involves three 
additional proteins, nicastrin, Aph-1 and Pen-2. The active site of γ-secretase requires the 
aspartyl protease activity of PS1 conferred by aspartate residues in adjacent 
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transmembrane domains of the C- and N-terminal cleavage fragments of PS1. Nicastrin, 
Pen-2 and Aph-1 are each critical components of γ-secretase and each may modify enzyme 
activity in specific ways and in response to physiological stimuli (Hebert, Godin et al. 
2003) (Cervantes, Saura et al. 2004; Nyborg, Kornilova et al. 2004).  
More recently, it has been shown that APP is also a substrate for caspase cleavage. Each of 
the four caspases, 3, 6, 7, and 8, have been shown to cleave APP in in vitro assays, and a 
major caspase site has been identified at Asp-720 (VEVD), resulting in the release of a 
fragment containing the last 31 amino-acids of APP (C31) (Lu, Rabizadeh et al. 2000). 
 
 
4. Gain of function versus loss of function hypothesis in AD : learning 
from mouse models 
 
Although many sophisticated mice APP models exist, none recapitulates AD cellular and 
behavioral pathology. Despite exhibiting a massive and often rapid accumulation of Aβ 
peptides, none of the examined APP Tg mice, carring FAD related mutations, replicated 
the full spectrum of AD pathology. Indeed the morphological resemblance to AD 
amyloidosis is impressive, but fundamental biophysical and biochemical properties of the 
APP/Aβ produced in Tg mice differ substantially from those of humans. The greater 
resilience of Tg mice in the presence of substantial Aβ burdens suggests that levels and 
forms deleterious to human neurons are not as noxious in these models. Notably, these 
animals failed to produce dementia-correlated neurofibrillary talngles (NFT) structures. 
Lack of NFTs and missing neuron loss are the most obvious difference in pathology 
between APP and APP/PS tg mouse models and the AD brain. This observation shows that 
mutated human APP and/or PS1/2 overexpression is not sufficient to induce the entire 
pathological cascade in mice suggests that the presence of Aβ is necessary but not 
sufficient to induce the tau-involved pathological changes typical of sporadic Alzheimer’s 
disease (SAD) and some familial Alzheimer’s disease (FAD) patients (Lamb, Bardel et al. 
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1999). These limitations may mean that with Tg mice, we are studying the direct effects of 
Aβ overproduction and deposition, but not AD. Moreover, eliminating amyloid deposits 
via Aβ immunization (Roher and Kokjohn 2002) may represent a cure in Tg mice, but 
regardless of the apparent total disruption of senile plaques in immunized patients with 
SAD, the successful clearance of these structures could neither reverse nor halt the 
progression of dementia. Indeed transgenic mice were widely used for testing AD 
therapeutic agents, but unfortunately, clinical trials resulted in unforeseen adverse events 
or negative therapeutic outcomes. Transgenic mice may suffer proportionately less 
deleterious effects than do AD patients, and therefore respond to amyloid 
disruption/removal therapies far better in terms of cognitive function recovery than even 
minimally demented humans who are contending with a broader scope of pathology. 
As a consequence, the preeminence of the amyloid cascade hypothesis as a unique 
pathogenic factor in AD is being reexamined.  The triple Tg (3xTg) mice, carrying the 
APP Swedish mutation K670N/M671L, the presenilin-1 M146V mutation, and the tau 
P301L mutation in the C57BL6 mouse background, were developed as an AD model 
(Oddo, Billings et al. 2004). This widely used Tg model develops intracellular Aβ and 
extracellular plaque deposits as well as the tau pathology similar to that observed in AD. In 
addition, these mice demonstrate altered long-term potentiation, synaptic dysfunction, and 
age-related learning deficits, and may have a role in testing therapeutic interventions 
against AD (Pietropaolo, Feldon et al. 2008) (Pietropaolo, Sun et al. 2008). One limitation 
of the 3xTg mouse model is that the key APP/Aβ and tau genes are overexpressed 
simultaneously by transcriptional forcing methods, whereas tau pathology emerges 
subsequent to Aβ production in AD.  The current status of  information from animal 
models suggest that a major scientific need is to understand the normal function of 
amyloid-β precursor protein (APP) and think how this may relate to the cell death in the 
disease process. Indeed a major concern about the amyloid hypothesis is that, despite the 
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fact that it is more than 20 years since the APP gene was cloned (Kang, Lemaire et al. 
1987), we have very little idea of its function and almost no idea as to whether Aβ has a 
function or not. One reason for this lack of knowledge is that APP knockout mice have 
very little overt phenotype (Heber, Herms et al. 2000). 
We also have no idea as to whether Aβ has a function or it is only a metabolic product of 
APP processing. As mentioned before mutations of the two presenilin-encoding genes, 
PSEN1 or PSEN2 which contribute to the onset of FAD, lead to an increase in the 
generation of the more amylodiogenic 42 aminoacid Aβ peptide (Aβ42). This shift in Aβ42 
abundance, coupled with the fact that Aβ42 is more amylodiogenic than the predominant 
Aβ40 species, is believed to accelerate the pathogenesis of AD. Therefore, inhibition of 
presenilin-dependent γ-secretase is considered a potential therapy for Aβ lowering and AD 
intervention according with Amyloid cascade hypothesis but clinical trials based on Aβ 
immunotepy, resulted in unforeseen adverse events, or failed to produce clinically 
beneficial outcomes (Heininger 2000). Neverthless, it should be taken in account that in 
addition to cleaving APP, the presenilins are involved in the intramembranous cleavage of 
numerous type-I integral membrane proteins (Lleo 2008) (Beel and Sanders 2008) (Parks 
and Curtis 2007) . Following receptor ectodomain shedding, the presenilins are involved in 
the cleavage of the membrane-tethered carboxylterminus of more that sixty-six membrane 
proteins, liberating their intracellular domains (ICDs) into the cytosol. In some cases these 
ICDs translocate to the nucleus and regulate the transcription of target genes, but other 
cleavage events are proposed to function as a means of clearing redundant protein 
fragments from the membrane following ectodomain shedding (Kopan and Ilagan 2004). 
Thus, the presenilins are involved in many signalling events independent of previously 
reported AD-associated activities. This has lead to the proposal that disruption of one or 
many of the presenilins activities within signalling complexes may also contribute to the 
pathogenesis of AD, or other disorders (Thinakaran and Parent 2004) (McCarthy 2005). 
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Consistent with these hypotheses, inactivation of PSEN1 gene in mice produced severe 
developmental abnormalities and perinatal lethality (Shen, Bronson et al. 1997) (Wong, 
Zheng et al. 1997) (Handler, Yang et al. 2000), indicating an essential role for PS1 in 
development. Indeed presenilins are widely and differentially expressed in mammalian 
tissues, with a broad cellular distribution suggesting multiple presenilin-dependent 
functions. They are located at the nuclear envelope, endoplasmic reticulum, Golgi 
apparatus, early secretory pathway and the plasma membrane. PS1 and PS2 share a high 
degree of homology (67%) with conservation between some transmembrane domains 
reaching 95% (Tomita and Iwatsubo 1999). Accordingly, there is significant similarity in 
their translated structures. Each of the presenilin genes encodes a multi-transmembrane 
protein and, although it is well over a decade since these proteins were discovered, a 
consensus has yet to be reached as to their precise topology (Laudon, Winblad et al. 2007) 
(Kornilova, Kim et al. 2006). Presenilin 1 plays essential roles in vivo, including neuronal 
differentiation and migration during embryonic development (Shen, Bronson et al. 1997) 
(Handler, Yang et al. 2000) (Wines-Samuelson and Shen 2005). However, PS1 conditional 
knock-out (PS1 cKO) mice, in which PS1 inactivation is restricted to the postnatal 
forebrain, show reduced Aβ generation and only subtle spatial memory impairment (Yu, 
Kim et al. 2001). Nevertheless, complete inactivation of both presenilins in the adult 
cerebral cortex results in hippocampal memory and synaptic plasticity impairments, 
followed by progressive neurodegeneration (Saura, Choi et al. 2004). 
The finding that PS1 mutations devoid of γ-secretase activity are associated with fronto-
temporal dementia ((Raux, Gantier et al. 2000) (Amtul, Lewis et al. 2002) (Dermaut, 
Kumar-Singh et al. 2004) also supports a possible link between loss of PS1 function and 
pathogenic mechanisms of dementia. The requirement of presenilins for synaptic plasticity, 
memory, and neuronal survival is mediated partly by the regulation of the cAMP response 
element-binding protein pathway, likely by γ-secretase dependent Notch cleavage and 
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signalling (Saura, Choi et al. 2004). Therefore, it is unlikely that γ-secretase inhibitors that 
affect Notch signaling will be useful as potential drugs for AD treatment. The hypothesis 
alternative to that of “Amyloid cascade hypothesis” is the “presenilin hypothesis” based on 
several in vivo observations. First, conditional inactivation of PS in the adult mouse brain 
causes progressive memory loss and neurodegeneration resembling AD, whereas mouse 
models based on overproduction of Aβ have failed to produce neurodegeneration. Second, 
whereas pathogenic PS mutations enhance Aβ42 production, they typically reduce Aβ40 
generation and impair other PS-dependent activities. Third, γ-secretase inhibitors can 
enhance the production of Aβ42 while blocking other γ-secretase activities, thus 
mimicking the effects of PS mutations. Finally, PS mutations have been identified in 
fronto-temporal dementia, which lacks amyloid pathology. Based on these and other 
observations, the partial loss of PS function seems to better explain neurodegeneration in 
the pathogenesis of AD. Moreover it has been proposed that Aβ42 may act primarily to 
antagonize PS-dependent functions, possibly by operating as an active site-directed 
inhibitor of γ-secretase. 
 
5. The APP function  
 
The normal functions of APP are not fully understood, but increasing evidence suggests it 
has important roles in regulating neuronal survival, neurite outgrowth, synaptic plasticity 
and cell adhesion (Mattson 1997). One possible function of full-length APP is as a cell 
surface receptor that transduces signals within the cell in response to an extracellular 
ligand (Kimberly, Zheng et al. 2001).  
Several functions have been proposed for this protein. For example, the extracellular 
domain of the protease nexin form of APP (APP751/770) is part of the clotting cascade 
(Xu, Davis et al. 2005). One possibility is that APPs (and possibly Aβ) are damage 
response proteins. While others have argued that Aβ might have some protective role (Lee, 
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Castellani et al. 2005), this possibility has not been rigorously investigated. The concern is 
that APP up regulation (and even perhaps Aβ deposition) is an acute response to damage, 
perhaps vascular damage, (Atwood, Bishop et al. 2002) (Kumar-Singh, Pirici et al. 2005) 
(Cullen, Kocsi et al. 2006) (Weller, Subash et al. 2008), in line with the role of APP in the 
regulation of blood clotting (Xu, Davis et al. 2005). However, neither a ligand nor 
downstream signaling cascades for APP have been clearly established. APP’s evolutionary 
conservation and the existence of APP-like isoforms (APLP1 and APLP2), which lack the 
Aβ sequence, however, suggest that these might have important physiological functions 
that are unrelated to Aβ production. The functional redundancy between mammalian APP, 
APLP-1, and APLP-2 became clear when it was first shown that APP/APLP-2 (von Koch, 
Zheng et al. 1997), and subsequently, APLP-1/APLP-2 double knockouts (Heber, Herms et 
al. 2000) (Wang, Yang et al. 2005), exhibit early postnatal lethality. APP/APLP-2 double 
knockouts have structurally and functionally defective neuromuscular synapses, with 
excessive nerve terminal sprouting, reduced synaptic vesicle numbers at the presynaptic 
compartment, and an observable aberrant apposition of presynaptic markers with 
postsynaptic acetylcholine receptors. APP/APLP-1 double knockouts are viable, but these 
also exhibit early postnatal death in conjunction with a haplodeficiency of APLP-2 (Wang, 
Yang et al. 2005). The triple knockouts are postnatally lethal and exhibit cranial 
abnormalities. These include cortical dysplasias resembling the phenotype found in human 
type II lissencephaly and a partial loss of cortical Cajal retzius (CR) cells (Herms, Anliker 
et al. 2004). These phenotypes of the APP/APLP-1/APLP-2 triple knockout are suggestive 
of defects in the survival of specific central nervous system cell types and the migration of 
neuroblasts. It is therefore clear that the APP and APPLs have important developmental 
and postnatal functions. 
Soluble N-terminal fragments of APP have been known to be neuroprotective. Recent 
findings have brought to light two possible functions of the APP family in the brain-
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regulation of neural progenitor cell proliferation. sAPPα, as does the ectodomain of APLP-
2 (Cappai, Mok et al. 1999), has been shown to be able to stimulate the proliferation of 
neural progenitor cells in vitro (Hayashi, Kashiwagi et al. 1994) (Ohsawa, Takamura et al. 
1999) and in vivo in the subventricular zone (SVZ) (Caille, Allinquant et al. 2004). The 
SVZ is one of two adult CNS sites that harbor neural progenitors that are capable of 
producing neurons in the adult brain (Conover and Allen 2002; Caille, Allinquant et al. 
2004). The results of Caile et al. have important implications for APP and APLP-2 
functioning as rather specific growth factors or co-factors for CNS neuroprogenitors. A 
possible endogenous source of APP or APLP ectodomains at the SVZ has in fact been 
noted in a subpopulation of cells, which expresses astrocytic markers (Yasuoka, Hirata et 
al. 2004). However, any specific sAPPα receptor has been identified and the respective 
proliferative signaling pathways dissected in detail (although MAP kinase activation by 
sAPP has been demonstrated (Greenberg, Koo et al. 1994). In fact, unlike the cytoplasmic 
C-terminus of APP, the N-terminus is surprisingly devoid of known specific neuronal 
interacting proteins. Candidate interacting proteins thus far known include ApoE (Barger 
and Harmon 1997) and the most recently identified F-spondin (Ho and Sudhof 2004). In 
this case, F-spondin binding to APP inhibits its proteolytic cleavage by BACE-1 and 
appears to modulate APP-dependent transactivation of Tip60-mediated transcription. F-
spondin has been shown to promote neurite outgrowth of both CNS (Feinstein, Borrell et 
al. 1999) and peripheral nervous system neurons(Burstyn-Cohen, Frumkin et al. 1998), as 
well as functioning in developmental axonal pathfinding and neuronal regeneration 
(Burstyn-Cohen, Tzarfaty et al. 1999) (Feinstein and Klar 2004).  
Although biochemical interaction studies have identified a plethora of molecules that 
interact with the APP intracellular domain (AICD), concrete evidence for a physiological 
significance of these interactions is often lacking. The cytoplasmic domain of APP is 
characterized by the GYENPTY motif, which is 100% conserved from C. elegans to 
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humans supporting the notion of its importance. This motif contains the consensus 
sequence for clathrin-coated pit internalization. Deletion of the cytoplasmic tail impairs 
internalization of cell surface APP and decreases Aβ secretion into conditioned medium by 
precluding endosomal–lysosomal APP processing (Essalmani, Macq et al. 1996) (Koo and 
Squazzo 1994) (LeBlanc and Gambetti 1994). The GYENPTY sequence is also a 
consensus motif for the binding of adaptor proteins that possess a phosphotyrosine binding 
domain (PTB), such as those in the X11, Fe65, and JIP families (Figure 4). These proteins 
bind the AICD in a phosphotyrosine independent manner and may affect the APP 
processing. Fe65 is an adaptor protein highly expressed in neurons (Fiore, Zambrano et al. 
1995) and is the first PTB-containing protein identified as ligand of the GYENPTY motif 
of the intracellular domain of APP and its hortologues APLP1 and APLP2. Fe65 and its 
hortologues Fe65L1 and Fe65L2 can modulate the APP processing in distinct ways that 
may be cell-type dependent, either promoting sAPP and Aβ secretion (Guenette, Chen et 
al. 1999) (Chang, Tesco et al. 2003) (Sabo, Lanier et al. 1999) either stabilizing immature 
APP and inhibiting sAPP  and Aβ secretion (Ando, Iijima et al. 2001). The same 
GYENPTY motif is implicated in the binding of X11 and mDab1. X11 is an adaptor 
protein (Borg, Yang et al. 1998) (Butz, Okamoto et al. 1998) that inhibits Aβ secretion 
(King, Perez et al. 2003), likely via impaired trafficking of APP to subcellular 
compartments containing active γ-secretase complex (King, Cherian et al. 2004), because 
has no inhibitory effect on γ-cleavage activity in a cell-free system. Indeed, human X11α 
and human APPswe double transgenic mice reveal a significant decline in Αβ40 levels in 
brain homogenates and rescue of age-dependent amyloid plaque deposition in brain 
compared to age-matched human APPswe transgenic control mice (Lee, Lau et al. 2003). 
Disabled-1 (Dab1), which plays a role in neuronal development (Homayouni, Rice et al. 
1999) (Howell, Lanier et al. 1999) has not clear effect on APP processing. Other proteins 
has been shown to interact may with the APP C-terminus, but little is known of their  
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The cytosolic tail of APP is reported with the GYENPTY motif in red. Some of the PTB-
containing proteins that interact with AICD are shown. It is rappresented the Tyr residue 











potential modulatory effects on its processing or the in vivo significance of their 
interaction, such as the JNK-interacting protein 1 (Jip1) (Matsuda, Yasukawa et al. 2001; 
Scheinfeld, Roncarati et al. 2002), Shc (Russo, Dolcini et al. 2002; Tarr, Roncarati et al. 
2002), Numb (Roncarati, Sestan et al. 2002), ARH (Noviello, Vito et al. 2003), Grb2 
(Zhou, Noviello et al. 2004) and AIDA (Ghersi, Vito et al. 2004). 
In our lab it has been shown that the proteolytic processing of APP is induced by activated 
PDGF receptor through a pathway involving the activation of Src and Rac1 (Gianni, 
Zambrano et al. 2003). This mechanism can be modulated by APP interactors. Infact, 
overexpression of Fe65 and Shc induce an increase of the APP processing, but via two 




6. The adaptor protein Fe65 
Yeast two-hybrid screens using the APP C-terminus as bait identified the adaptor protein 
Fe65 (Fiore, Zambrano et al. 1995) (Russo, Faraonio et al. 1998) (Zambrano, Buxbaum et 
al. 1997). Fe65 is expressed at high levels in neurons (Bressler, Gray et al. 1996). Human 
and mouse Fe65 genes have an alternatively spliced isoform with an exon present only in 
the neuron-specific transcript(Hu, Hearn et al. 1999). In adult mouse brain Fe65 is highly 
expressed in neurons in the hippocampus, cerebellum, thalamus, and midbrain, with some 
expression in a subset of astrocytes in the hippocampus. Fe65 expression is also 
developmentally regulated, with levels declining after embryonic day 15 and increasing 
again progressively from postnatal day 10 to adulthood (Simeone, Duilio et al. 1994) 
(Kesavapany, Banner et al. 2002).  
Fe65 is a member of a protein family consisting of Fe65, Fe65-like (Fe65L or Fe65L1) 
(Guenette, Chen et al. 1996) and Fe65L2 (Duilio, Faraonio et al. 1998). The members of 
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the Fe65 family share a high grade of sequence homology in the three functional domains 
and all of them can bind the APP family members cytosolic tail although the Fe65-APLP1 
interaction is the most affine.(Guenette, Chen et al. 1996; Duilio, Faraonio et al. 1998). A 
difference between the members of Fe65 family is in the tissue specificity. Fe65 is highly 
expressed in neurons; Fe65L1 is ubiquitously expressed; and Fe65L2 is very abundant in 
testis and brain (Duilio, Zambrano et al. 1991; Simeone, Duilio et al. 1994; Guenette, Chen 
et al. 1996). Genetic models suggest a redundant function of the Fe65 family members. 
Fe65 knock out mice appear normal, but double mutants Fe65-/-/Fe65L1-/- show cortical 
dysplasia, mislocalization of CR neurons, distruption of basal membrane, with a phenotype 
similar to that observed in the triple knock out mice of the APP family and to the PS1 
knock out. A possible explanation of the overlapping phenotype is the impairment of a γ-
secretase-dependent signalling involving the APP-Fe65 interaction, thus implying a role of 
APP-Fe65 signaling as effector of normal neuronal positioning in brain development.  
The Fe65 protein contains three protein interaction domains: a WW domain in the N-
terminus and two PTB domains in the C-terminus, with distinct binding specificities. The 
PTB domains of Fe65 have distinct features compared to those present in proteins as Shc 
and IRS-1. They lack a Phe residue, which is conserved in all known PTBs and in Fe65 is 
replaced by a Cys (Zambrano, Buxbaum et al. 1997) and they can bind the GENPTY motif 
when the tyrosine is not phosphorylated (Margolis, Borg et al. 1999). The WW domain is 
one of the smallest protein domain composed of 40 amminoacids, which is found in a wide 
range of signaling molecules, and binds proteins containing proline-rich motif. The WW 
domain of Fe65 belongs to the II group of WW domains that recognizes a PPPPLP 
consensus sequence (Kay, Williamson et al. 2000).  
In the literature several partners of the three protein interaction domains of Fe65 have been 
described. The WW domain interacts with Mena (mammalian enabled), which binds actin 
and thus links Fe65 and APP to cytoskeletal dynamics and cellular motility and 
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morphology (Ermekova, Zambrano et al. 1997). Indeed, Fe65 and APP colocalize at 
synaptic sites and in distal domains of neuronal growth cones, particularly actin-rich 
lamellopodia (Sabo, Ikin et al. 2003). Another ligand of the WW domain of Fe65 is the 
active form of the tyrosine kinase c-Abl, which mediates the phosphorylation of Fe65 on 
tyrosine 547 within its second PTB domain and modulates its nuclear function (Russo, 
Faraonio et al. 1998). It has been hypothesized that Fe65 might recruit c-Abl to the C-
terminus tail of APP to allow the phosphorylation of the tyrosine Y682 by the c-Abl, which 
can itself bind the phosphorylated AICD through its SH2 domain (Zambrano, Bruni et al. 
2001; Perkinton, Standen et al. 2004). As part of my thesis project I described a new 
complex of Fe65 with the nucleosomal assembly protein SET that requires an overlapping 
region of the WW domain (Telese, Bruni et al. 2005) and is able to modulate its nuclear 
function.  
The PTB1 domain of Fe65 binds the low density lipoprotein receptor related protein (LRP) 
which serves as a receptor for ApoE and α-2 macroglobulin that scavenge secreted Aβ 
(Trommsdorff, Borg et al. 1998). Recently, it has been reported that Fe65 binds with its 
PTB1 domain another member of the LRP family, the ApoER2 (Hoe, Magill et al. 2006). 
The complex between Fe65 and the members of the LDL-related proteins might affect the 
APP processing. The PTB1 domain of Fe65 also binds the transcription factor complex 
CP2–LSF–LBP-1c (Zambrano, Minopoli et al. 1998) and this interaction is implicated in 
the regulation of transcription of GS3Kβ (glycogen synthase kinase−3β) (Kim, Kim et al. 
2003) and timidilate synthase (Bruni, Minopoli et al. 2002). Another nuclear ligand of the 
PTB1 domain of Fe65 is the histone acetyl transferase Tip60 (Cao and Sudhof 2001). 
The PTB2 domain of Fe65 binds the APP C-terminus. This interaction requires the 
GYENPTY motif as well as threonine-668, 14 residues N-terminal to the internalization 
sequence. Phosphorylation of threonine-668 of APP impairs Fe65 interaction, suggesting 
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that the interaction of Fe65 with APP may be differentially regulated by its 
phosphorylation–dephosphorylation status (Ando, Iijima et al. 2001).  
 
7. Neurodegeneration and DNA damage response. 
 
Neurogenerative diseases are a group of pathologies affecting the central nervous system 
whose common feature is the deterioration of neuronal functions. Neuronal cells are fully 
differentiated post-mitotic cells, highly specialized for the processing and transmission of 
cellular signals. The manteinance of genomic integrity has crucial meaning for these cells 
considering their inability to proliferate and substitute damaged cells. Since they are 
irreplaceable and should survive as long as the organism does, they need elaborate, 
stringent defense mechanisms to ensure their longevity. Neurons display high rates of 
transcription and translation, which are associated with high rates of metabolism and 
mitochondrial activity. The amount of oxygen consumed by the brain relative to its size far 
exceeds that of other organs. This high activity coupled with high oxygen consumption 
creates a stressful environment for neurons: damaging metabolic by-products, primarily 
reactive oxygen species (ROS), are constantly attacking neuronal genomic and 
mitochondrial DNA (Barzilai, Biton et al. 2008) (Katyal and McKinnon 2007) (Fishel, 
Vasko et al. 2007) (Weissman, de Souza-Pinto et al. 2007) (Halliwell 2006) (LeDoux, 
Druzhyna et al. 2007) and (Ryter, Kim et al. 2007). Neurons ensure their longevity and 
functionality in the face of these threats by elaborate mechanisms that defend the integrity 
of their genome. The DNA damage response is a key factor in the maintenance of genome 
stability. It is now clear that diverse mechanisms encompassing cell cycle regulation, repair 
pathways, many aspects of cellular metabolism, and cell death are inter-linked and act in 
consort in response to DNA damage. One of the most powerful activators of the DDR is 
the double strand break (DSB) in the DNA (Helleday, Lo et al. 2007). Eukaryotic cells 
employ two major mechanisms to repair DSBs: nonhomologous end-joining (NHEJ), an 
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error-prone ligation mechanism, and a high-fidelity process based on homologous 
recombination (HR) between sister chromatids that operates in the late S and G2 phases of 
the cell cycle (van Gent and van der Burg 2007) (Wyman and Kanaar 2006). But, the 
overall cellular response to DSBs goes far beyond repair. This broad, powerful signaling 
network works to affect chromatin organization and a large number of cellular systems 
(figure 5) (Bakkenist and Kastan 2004) (Shiloh 2003) (Harrison and Haber 2006) (Shiloh 
2006). One of its hallmarks in proliferating cells is the activation of cell cycle checkpoints 
that temporarily halt the cell cycle while damage is assessed and processed (Jeggo and 
Lobrich 2006) (Bartek and Lukas 2007). Defects in the DNA damage response in 
proliferating cells can lead to cancer while defects in neurons result in neurodegenerative 
pathologies (Figure 5). In animal models, ectopic expression of oncogenes in terminally 
differentiated cells, including neurons, has been shown to induce apoptosis rather than 
proliferation. For instance, mice transgenic for the SV40 T antigen, which is normally 
oncogenic in cycling cells, show progressive degeneration of Purkinje neurons to which 
transgene expression was targeted (Klein, Longo-Guess et al. 2002). Other genetic models 
suggest that cell-cycle reactivation in neurons precedes or is at least coincident with 
neuronal apoptosis. 
The cell cycle in a normally cycling cell proceeds through four distinct phases, whereas 
cell-cycle reactivation in a post-mitotic neuron (by a stimulus such as excitotoxicity, 
growth factor withdrawal or overwhelming DNA damage) leads to apoptosis. Several 
genetic deficiencies in enzymes that detect or repair DNA damage can induce the apoptosis 
of specific neuronal populations or further sensitize them to genotoxic stresses. A good 
link  between defects in DNA repair, malignancy and neurodegeneration are seen with 
loss-offunction mutations in ataxia telangiectasia-mutated (ATM), a member of the 
phospatidylinositol-3 (PI3) kinase superfamily with multiple functions and protein targets. 
ATM can activate repair proteins such as the Rad50–Mre11–Nsb1 complex in response to 
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Figure 5: Effects of defective DDR pathways on the central nervous 





























 Neurons are characterized by elaborate structure and function, perhaps more than any 
other cell type. The combination of their critical function, post-mitotic nature, finite 
number and high oxygen consumption demands a robust DNA damage response. 
Reduction in DNA repair proteins has been associated with various neurodegenerative 
pathologies such as typical late onset, chronic diseases like Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) or monogenic disorders such as the genomic instability 
syndromes, Ataxia telangiectasia, Nijmegen breakage Syndrome, Cockayne’s syndrome 
(CS) and Trichothiodystrophy (TTD) 
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 DNA double-strand breaks created, for instance, by ionizing radiation, but when the DNA 
repair machinery is overwhelmed, ATM can also activate p53 and Chk1 to induce cell-
cycle arrest or apoptosis. In mouse models deficiency of ATM causes a progressive 
apoptosis of nigral dopamine neurons followed by degeneration of striatal projection 
neurons (Eilam, Peter et al. 2003) (Eilam, Peter et al. 1998). The neurodegenerative 
phenotype early in the human disease ataxia-telangiectasia is restricted to Purkinje and 
granule cells of the cerebellum but broadens considerably with age and may extend to the 
basal ganglia (Gibb and Lees 1989) (Agamanolis and Greenstein 1979). ATM and ATM-
related protein (ATR) function at a nexus of neurodevelopmental and DNA repair 
activities; specific biallelic defects in these lead not only to cerebellar degeneration but 
also to microcephaly (Seckel syndrome) and, in conjunction with p53 inactivation, tumors 
of the central nervous system such as medulloblastoma (Lee and McKinnon 2007). 
A convergence of biochemical, genetic and epidemiologic data has implicated certain 
genes in both oncogenesis and neuronal dysfunction. These include the tumor suppressors 
ATM and PTEN and possibly parkin. Typical late onset, chronic diseases are Alzheimer’s 
disease (AD) and Parkinson’s disease (PD), while monogenic disorders such as the 
genomic instability syndromes are characterized by early onset and acute manifestation. 
There are common denominators between these two groups of diseases, and accumulation 
of DNA damage is one of them (Fishel, Vasko et al. 2007) (Halliwell 2006) (Rutten, 
Schmitz et al. 2007) (Rutten, Korr et al. 2003) (Cotman and Su 1996) (Itzhaki 1994) 
(Robbins 1987). All of these disorders impair “brain functionality” to various degrees, 
defined by total input and output of the brain’s neuronal circuits. Neurodegenerative 
disorders deregulate the activity of specific circuits, affecting their organization, cell 
numbers, cellular functionality, and interactions between cells and circuits. It is reasonable 
to assume that DDR components that affect early onset neurodegenerative diseases can 
also be involved in late onset neurodegenerative diseases such as PD or AD. Increased 
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oxidative stress; accumulation of oxidative  damage; reduced NHEJ; accumulation of 
DSBs and SSBs; reduction in MRN complex components; activation of cell cycle program. 
It will be of clinical interest to determine which of these genes and their molecular partners 
would be useful biomarkers or therapeutic targets and at what stage of disease such 
applications would be most effective. In addition, determining which aspects of cell-cycle 
control in normal neuronal development are recapitulated in neurodegeneration and which 
are unique to each process may help optimize conditions for regenerative therapies based 
on stem-cell differentiation and transplantation. 
 
The aims of the thesis 
Fe65 is a nuclear protein interacting with Tip60, SET, c-Abl and CP2/LSF. Among these 
nuclear partners Tip60 and SET are involved in chromatin remodelling. The high 
sensitivity to genotoxic stress induced by the Fe65 suppression both in vitro and in vivo led 
us to investigate the involvement of Fe65 in chromatin remodelling during DNA repair. 
This hypothesis was supported by the fact that the histone acetyl-transferase Tip60 is a 
component of NuA4 complex involved in the early streps of chromatin decondensation 
during DNA repair. To this aim I investigated the role of Fe65 and its main interactor APP 
in the cellular response to DNA damage. Most of the data shown in this thesis have been 
published in the following papers: (Stante, Minopoli et al. 2009) (Minopoli, Stante et al. 










MATERIALS AND METHODS  
 
1. Generation of Fe65 knock out mouse embryonic fibroblasts (MEFs) 
 
For generation of mouse embryo fibroblast lines, E13.5 embryo bodies devoid of heads 
and liver were tripsynized and plated in DMEM (Invitrogen) supplemented with 10% 
Newborn Calf Serum (HyClone), 1% penicillin and streptomycin, 1% MEM-non-essential 
amino acids (Invitrogen), 1.6 mM 2-mercaptoethanol. Immortalized lines were obtained 
following spontaneous recovery of the primary cultures from proliferation crisis. These 
lines were cultured in DMEM supplemented with 10% fetal bovine serum. 
Three Fe65 knock out (KO) immortalized lines  (# 3, # 8 and # 9) were obtained from three 
independent Fe65 KO mice. 
 
2. DNA damaging agents treatment and irradiation of mice 
Etoposide (VP-16, Calbiochem, 100 mM stock in DMSO) was added to the medium at 
final concentration of 15 µM for comet assay analysis or 40 μM for western blot analysis. 
Cells were then incubated at 37°C and 5% CO2 for 30 minutes before comet assay or for 2 
hours before lysis and protein extraction. H2O2 was diluted from a 30 % w/w (8.8 M 
stock) aqueous solution (Sigma) immediately before cell treatment in complete conditioned 
medium at the final concentration of 10µM. 
Cells were incubated at 37°C and 5% CO2 for 30 min or 1 hourbefore Comet Assay. To 
induce genotoxic stress in mice, these were exposed to 0.5 or 1 Gy doses of 6 MV X-ray 






3. Comet assay 
The neutral comet assay was carried out according to manufacturer’s recommendations 
(Trevigen, Gaithersburg, MD). After treatment described before cells were trypsinized and 
resuspendend in cold PBS at 106 cells/ml. All passages were done on ice. 
For each point 10 µl of resuspended cells were added to 100 µl of melted agarose (37°C) 
and rapidly spread on slides. Agarose was allowed to solidify for 30 min. at 4°C and then 
slides were incubated for 30 min in lysis buffer and for 40 min in alkaline solution 
(pH>13). Comet tails were generated by a 10 min electrophoresis in TBE buffer at 20 V at 
room temperature. Slides were stained with Syber Green and DNA migration was analyzed 
by fluorescence microscopy (Leica DMS 4000B). Tail moment and tail length were 
calculated using the software CometScoreTM (TriTek Corporation). A minimum of 50 
cells per experiment was analyzed. All the experiments were done in triplicate. The 
Student’s t-test was used to measure statistical significance. 
 
4. Cells culture conditions and transfection of shRNAs and siRNAs 
NIH3T3, Hepa 1-6 and murine neuroblastoma cell line N2A were cultured under standard 
conditions and transfected with lipofectamine 2000 (Invitrogen) according to manufacture 
instructions. Fe65 silencing was obtained by transfecting pSM2 retroviral shRNAmir 
vectors (Open Biosystems, cat #RMM1766-9351830) or siRNAs (Dharmacon, cat#LQ-
042929); APP and APLP2 silencing was obtained by transfecting siRNAs (Dharmacon, 
cat#L-043246 and L- 042937, respectively), following the manufacturer’s instructions. 
Non-silencing siRNAs were used as a control (Dharmacon, cat#D-001810-10-20). 48 
hours upon transfection of Fe65 shRNA or non silencing shRNA cells were selected with 
puromycin at final concentration of 5 µg/ml for 2-3 days until cells in non transfected 
control plate were died to enrich the pool of transfected cells.  
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Puromycin resistant cells were then plated at desired confluence to perform following 
experiments. siRNAs transfected cells were used for following experiments 48 hours upon 
transfection. Transfection was carried out using the siRNAs at final concentration of 
100nM using 1:1 Lipofectamine : siRNAs ratio. In all cases the silencing of proteins was 
evaluated by western blot analysis with specific antibodies.  
 
5. Generation of the recombinant constructs in pRcCMV vector 
pRC-CMV-NES-myc and pRC-CMV-mutNESmyc vectors were obtained by cloning in 
the pRC-CMV (Invitrogen) the sequence of NESmyc and mutNES-myc using NotI / ApaI 
restriction sites. NES-myc and mut NES-myc ds DNA were obtained by annealing 
synthetic oligonucleotides (see sequence below) using the following annealing buffer : 
100mM NaCl, 50 mM Hepes pH 7.4.  
3µg of forward oligo and 3µg reverse oligo were added to the annealing buffer in a final 
volume of 50 µl and incubared in a thermal cycler as follow:  
90° C 4 min. 
70° C 10 min. 
37° C 20 min. 
20° C 10 min. 
The Fe65-NES and Fe65-NESm constructs were obtained by cloning into the pRC-CMV-
NESmyc and pRC-CMV-mutNES-myc vectors, respectively, the FE65 cDNA amplified 
by PCR with the primers listed below and digested with appropriate restriction enzymes. 
All the Fe65 mutants were cloned in the pRcCMVmutNES-myc vector using HindIII and 
NotI restriction sites. The sequences of the oligonucleotide primers used in this work to 




















 The following primers were used to amplify  the wild type Fe65 cDNA and the point 
mutation mutants ( C655F and YYW->AAA) using respectively the wild type template or 
constructs carrying the specific mutations. 
 
Fe65-HindIII for : 5’CCCAAGCTTAAGGCCATGTCTGTTCCATCATCCC3’ 
Fe65-Not1 rev : 5’CCCGCGGCCGCTGGGGTCTGGGATCCTAG3’ 
 




ΔupWW  Hind III for: 5’CCCAAGCTTAAGGCCATGTCCGATCTACCGGCTG3’ 
 
ΔWW Hind III for: 5’CCCAAGCTTAAGGCCATGCAGGGGAACAGTCCC3’ 
 
 
The ΔPTB1 mutant was amplified by overlapping PCR using the following primers: 
 
ΔPTB1 Hind III for: 5’CATGCCCAGCCCATCGTCAGCCGCTGCTTGGTAAATGGACTC3’ 
 
 
ΔPTB1 Hind III for: 5’GAGTCCATTTACCAAGCAGCGGCTGACGATGGGCTGGGCATG3’ 
 
 
The ΔPTB2 was amplified using Fe65 HindIII for primer and 
 





                                     
6. Immunofluorescence 
Cells were fixed in 4% paraformaldehyde for 10 min, permeabilized for 10 min in 0.2% 
Triton X-100, and blocked in 10% BSA for 1 h at room temperature. The slides were 
incubated with primary antibody for 1 h, washed in PBS, and incubated with Alexa Fluor 
conjugated secondary antibodies (Molecular Probes, Eugene, OR) for 1 h at room 
temperature. Cells were washed in PBS and mounted using Vectashield mounting medium 
with DAPI (Vector Laborator). Images were captured with an inverted microscope 
(DMI4000, Leica Microsystems).  
 
7. Immunoprecipitation , western blot and antibodies 
For the preparation of the cellular extracts, monolayer cultures were harvested in cold 
phosphate-buffered saline and sonicated in lysis buffer (50 mM Tris·HCl, pH 7.5, 150 mM 
NaCl, 0.5% Nonidet P-40, 10% glycerol, 0.4 mM EDTA, 50 mM NaF, 1 mM sodium 
vanadate, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor tablets). The 
extracts were clarified by centrifugation at 16,000 × g at 4 °C, and the protein 
concentration was determined by the Bio-Rad protein assay according to manufacturer's 
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instructions. For immunoprecipitations, appropriate amount of antibodies was incubated 
with 1.5 mg of protein lysates for 2 h at 4 C, followed by a 1 hour incubation with Protein 
A–Sepharose. Immunoprecipitates were washed three times in lysis buffer. Proteins 
released by boiling in SDS sample buffer were separated by Novex Bis–Tris 4–12% 
polyacrylamide gels (Invitrogen) and analysed by specific antibodies. 50 μg (or the 
indicated amounts) of each extract were electrophoresed on 4-12% SDS-polyacrylamide 
gradient gel under reducing conditions. Western blot experiments were carried out as 
described (Zambrano et al. 1998). For p-ATM western blot, proteins were separated on 5% 
low bis acrylamide gels (acrylamide:bis ratio 5:0,17). The antibodies used and their 
dilutions were: anti-H2AX (Bethyl Laboratories, Inc., 1:1000); anti-p53 (Ab-1) (Upstate 
Biotechnology, 10 μg/ml), antiphospho- p53 (Cell Signaling, 1:1000), anti-Fe65 (9); anti-
γH2AX (Ser139) (Cell Signalling Technology, 1:1000); anti- phospho ATM (Ser 1981) 
(Cell Signaling, 1:1000), anti-APP C-term (A8717 Sigma, 1:4000), anti-NBS (Santa Cruz, 
1:500), anti-lamin B (Santa Cruz, 1:250), anti-β- actin (Sigma, 1:1000), anti-myosin (Santa 
Cruz, 1:1000), anti-tubulin (Sigma, 1:1000) APLP2 (Calbiochem 1:5000). Horseradish 
peroxidase-conjugated goat polyclonal anti-rabbit and anti-mouse IgG were purchased 
from GE Healthcare. The rabbit polyclonal anti-FE65 antibody was described in (Duilio, 
Faraonio et al. 1998) 
 
 
8. Histone Association Assay 
 This procedure is a modification of the earlier described ChIP protocol (Liu, Wang et al. 
2008). Cells were treated with formaldehyde at a final concentration of 1% for 15 min. The 
reaction was quenched with the addition glycine to a final concentration of 125 mM. 
Nuclei were prepared as described in Zambrano et al. 1998, lysed in ChIP lysis buffer 
(50mMHepes-KOH pH 7.5, 150 mMNaCl, 1 mMEDTA, pH 8.0, 1% Triton X-100, 0.1% 
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sodium deoxycholate and protease inhibitors) and chromatin was sheared by sonication to 
_2 kb to 500 bp. The extract was centrifuged for 5 min at 20,000 _ g at 4 °C. For each 
histone H3 immunoprecipitation, _1 mg of nuclear extract (as measured by the Bradford 
assay) was incubated with 8 _g of rabbit polyclonal histone H3 antibody (Upstate). Equal 
amount of Rabbit IgG (Sigma) was used as negative control. Samples were incubated 
overnight at 4 °C with shaking. 20 _g of single-stranded herring spermDNAand 25_L of 
proteinASepharose beads were added and incubated at 4 °C with shaking for 90 min. The 
beads were washed twice in ChIP lysis buffer, once in ChIP lysis buffer with 500 mM 
NaCl, once in ChIP washing buffer (10 mM Tris pH 8.0, 0.25 M LiCl, 0.5% Nonidet P-40 
and 0.5% sodium deoxycholate). The beads were washed once more in ChIP lysis buffer 
and resuspended in 50 _L of Laemmli loading buffer. The input controls and 
immunoprecipitates were boiled for at least 30 min to reverse the cross-links. Chromatin-
associated Fe65 was analyzed by SDS/PAGE and Western blot with Fe65 antibody. 
 
 
9. Chromatin Immunoprecipitation. 
Cells were treated with 1% formaldehyde for 10 min at room temperature and 
formaldehyde was then inactivated by the addition of 125mMglycine. Chromatin was then 
sonicated to an average DNA-fragment length of 200–1,000 bp. Soluble chromatin extracts 
were immunoprecipitated using Tip60, TRRAP, acetyl-histone H4, Fe65 or myc antibodies 
and goat or rabbit IgG as a control. Supernatant obtained without antibody was used as 
input control. The amount of precipitated DNA was calculated by real-time PCR relative to 
total input chromatin, and expressed as percent of total chromatin according to the 
following formula: 2ΔCt x 10, where Ct represents the cycle threshold and ΔCt = Ct(input) 
–Ct(immunoprecipitation) (Frank, Heim et al. 2002). All the experiments have been done 
at least as independent triplicates and the Student’s t-test was used to measure statistical 
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significance. Primer sequences used to amplifying the 0.5, 2 and 10 Kb regions 
downstream I-SceI site in NIH-GS clones (see below) are: 
0.5 Kb F      CCACTACCTGAGCACCCAGTC 
 
0.5 Kb R      GGTCACGAACTCCAGCAGGA 
  
2 Kb F         TCAGGTGCAGGCTGCCTAT 
 
2 Kb R         TTTGTGAGCCAGGGCATTG 
 
10 Kb F        TTCTGATGGAATTAGAACTTGGCAA 
 
10 Kb R       GAACGAGATCAGCAGCCTCTGT 
 
Oligo sequences used to amplifying endogenous loci are listed below: 
 
POLII Start F         5’ GATTCTGGGAACGTCGGAGA 3’ 
POLII Start R        5’AAAGCTGGAGACGGGAAGC 3’ 
POLII 17Kb up F   5’GCTCAGCCAACCACAGTGATT 3’ 
POLII 17Kb up R     5’CCTGTCCGAGCGGTGATG 3’ 
POLII 20Kb down F   5’CCCTTGGCACCTTCTTTGG 3’ 
POLII 20Kb down R     5’ATCAGAGCTAAAACAGAAGTGAGTCAA 3’ 
ALBUMIN Start F         5’TGGCAAAATGAAGTGGGTAACC 3’ 
ALBUMIN Start R         5’CGAAACACACCCCTGGAAAA 3’ 
ALBUMIN 10 Kb up F    5’GCTCCATTTCTCACTGTAATACCATTT 3’ 
ALBUMIN 10 Kb up R     5’CCAGTCACCCAGCTAAAACTTAAAA 3’ 
ALBUMIN 15 Kb down F  5’CTGGAAGAGGAAACTGGGTGAT 3’ 
ALBUMIN 15 Kb down R    5’ GACCCTTTGACCACGCAACT 3’ 
GST Start F  5’CACATCTAAGCGGTCCTGGTCTA 3’ 
GST Start R   5’TGAGACTGAAGCACAGAAAAGCA 3’ 
GST a 5Kb down F          5’CCTTCCTCCACTTTTGAGTCTGA 3’ 
GST a 5Kb down R          5’TCCCTACGGTCATGTCAATCC 3’ 
GST Start F    5’CACATCTAAGCGGTCCTGGTCTA 3’ 
GST Start R   5’ TGAGACTGAAGCACAGAAAAGCA 3’ 
 
All primers were used to a final concentration of 4 µM in a 20 µl Real Time reaction 
containing 10 µl of Syber Green 2X ( Applied Biosystems) and 1 µl DNA.   
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10. MNase ASSAY 
 
Micrococcal Nuclease Digestion was performed as described in ref. 1. Briefly, 106 cells 
were Dounce homogenized in RSB buffer (10 mM Tris_HCl pH 7.4, 10 mM NaCl, 3 mM 
MgCl2, 0.5% Nonidet P-40) containing 1 mM phenylmethylsulfonyl fluoride, 1 mM 
Na3VO4, 1 mM DTT and protease inhibitors mixture, and incubated on ice for 15 min. 
Samples were washed twice with RSB buffer and digested with 2.5 units of micrococcal 
nuclease (USB) in digestion buffer (15 mM Tris_HCl pH 7.5, 60 mM KCl, 15 mM NaCl, 1 
mM CaCl2, 3 mM MgCl2, 20% glycerol, 15 mM β-mercaptoethanol) for the indicate 
times. Digestion was stopped by adding 1 volume of stop solution (50mMTris pH 7.5, 
150mMNaCl, 50mMEDTA, 0.3% SDS). DNA was phenol/chloroform extracted, 
precipitated with isopropyl alcohol and separated using 1.2% agarose gel electrophoresis. 
 
11. Cloning of mutants into p-Babe-puro retroviral vector 
 
p-Babe puro retroviral vector was modified by destroying the Hind III restriction site and 
by inserting an artificial polylinker sequence (p-Babe-puroM7). To destroy the original 
HindIII site, the vector was linearized with Hind III restriction enzyme and the sticky ends 
were filled in by using the Klenow large fragment before the ligation reaction with T4 
DNA ligase to obtain a p-Babe-puro NO HINDIII vector. The artificial polilynker 
containing the HindIII and ApaI restriction sites was obtained by annealing in vitro the 
following oligonucleotides : 
poliBamHI forward :   
5’-GATCCACCTGCAGCAAGCTTCTCGAGACGCGTGGGCCCTCGCGAG-3’ 
poliEcoRI reverse : 
5’-AATTCTCGCGAGGGCCCACGCGTCTCGAGAAGCTTGCTGCAGGTG-3’ 
and was cloned into the p-Babe-puro NO HINDIII vector BamHI/EcoRI digested, to obtain 
a p-Babe-puro NO HIND III/poli vector. The resulting vector was used to clone into 
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HindIII/ApaI sites the Fe65 wt and mutants DNA fragments obtained by HindIII/ApaI 
digestion of correspondent pRC-CMV-mutNES-myc construcs described before. 
 
12. Retroviral production and infection 
Fe65wt and Fe65 mutants retroviral vectors were trasfected into LinX packaging cell line 
(Catalog #: LNX1500) by using calcium phosphate method. 48 hours after transfection 
viral supernatants were collected, filtered, supplemented with 8 µg/ml polybrene, and 
combined to infect early Fe65 KO Mefs. Infection was performed twice to ensure high 
efficiency. Incubation of cells with retrovirus containing supernatant was carried out for 5-
6 hours at 37°C and 5% CO2.  
Cells were then incubated with fresh medium and reinfected 24h after the first infction. 48 
hours the first infection, cells were selected with puromycin (2.5 µg/ml) for 4 days and 
used for following experiments. Effective infection was confirmed by Western blot 
analysis. 
 
13. Generation of NIH-GS cells and measurement of repair efficiency. 
 
 
To obtain the NIH-GS clones, NIH3T3 cells were transfected with pDRGFP plasmid (SI 
ref. 2). 48 hours after transfection, cells were selected with puromycin (3 μg/ml) for 5 days. 
Puromycin-resistant colonies were pooled and amplified under puromycin selection to 
obtain NIH3T3-G stable clones. The latter were then transfected with the I-SceI-ER vector 
(see below). 48 hours after transfection, cells were selected for 9 days with 900μg/ml G418 
and 2μg/ml puromycin. Double resistant colonies were pooled and amplified. 







using as template the pBSKS+ER vector kindly provided by Caterina Missero and inserted 
into the HindIII/NotI sites of β-actin promoter vector (Parisi, Passaro et al. 2008) to obtain 
the an ER- β-actin promoter vector. 
The Sce-I cDNA was amplified from pCβASce plasmid kindly provided by prof. 
Avvedimento using the following primers: 
SceI BamHI forward:                                                          
5’-CCCGGATCCAAGGCCATGGGATCAAGATCGCCAAAAAAG-3’ 
 
SceI no stop SmaI reverse: 5’-CCCCCCGGGCTTTCAGGAAAGTTTCGGAGGAG-3’  
 
and was cloned in frame into the BamHI/HindIII filled ER-β-actin promoter vector, to 
obtain a Sce-ER plasmid. 
Sequences of the oligonucleotide pairs used in ChIP experiments are reported before (see 
Chromatin Immunoprecipitation). NIH-GS cells were exposed to 1 µM 4-OH-tamoxifen 
for 6 hours before ChIP experiments. For FACS analysis NIH-GS cells were exposed to 1 
µM 4-OH-tamoxifen for 48 hours to allow cells growth upon I-SceI-ER induction. In both 







14, FACS analysis 
 For FACS analysis NIH-GS clones were transfected with Fe65 or APP+APLP2 siRNAs or 
control siRNA or with Fe65 constructs. 24 hours from transfection cells were treated with 
tamoxifen. 48 hours after I-Sce-I-ER induction, cells were harvested, resuspended in PBS 
at 200,000 cells/ml and GFP positive cells were counted with FACScanto (BD 
Biosciences, San Jose, CA) instrument. Each 
experiment was performed at least in triplicate by counting 30,000 events per sample. The 







































1. Fe65 KO MEFs are highly sensitive to DNA damage 
 
To explore the functions of Fe65 and of the Fe65/APP complex we generated Fe65 knock 
out mice. These mice do not show any obvious phenotypes up to 12 months of age. The 
most conceivable explanation of these findings is that Fe65L1 and/or Fe65L2 compensate 
for the absence of Fe65, thus allowing the animal to develop and live normally. However, 
we explored whether in stressful conditions the absence of Fe65 protein in Fe65 knock out 
cells could be not enough to arrange an adequate cellular response and this could result in a 
defect that unmasks the function of the protein. To this aim we generated mouse 
embryonic fibroblasts (MEFs) from Fe65 knock out (KO) mice and from wild type (WT) 
mice as control cell lines. Immortalized cell lines established form them were amplified 
and used as experimental system to evaluate the cellular response to genotoxic agents such 
as etoposide or hydrogen peroxide (H2O2) in the absence of Fe65. 
The first experiment we performed on this cell lines was the Comet Assay, also known as 
Single Cell Gel Electrophoresis, that allows to evaluate the susceptibility to DNA 
damaging agents by measuring the length of the tail (tail length) and the amount of DNA in 
the tail (tail moment) in every single cells upon electrophoresis on a solid support and 
staining with a double-strand DNA binding dye (Sybr Green). In Figure 6A are shown 
Comet Assay fluorescence microscopy images from WT and Fe65 KO MEFs. The 
exposure to 15 μM etoposide or 20 μM H2O2 for 30 minutes, has only marginal effects on 
wild type MEFs whereas three Fe65 KO MEFs, derived from three independent embryos, 
showed high levels of damaged DNA. Wild type MEFs show a dose dependent increase of 
DNA damages upon the exposure for 30 minutes to etoposide or H2O2 indeed the measure 
of tail moment in the comet assay demonstrated that at concentrations of 15 μM, the two 
agents have only marginal effects on these cells (Figure 6B). On the contrary, three Fe65 
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KO MEFs derived from three independent embryos showed at these low concentrations 
























































A : Fluorescence microscopy images of cells upon Comet Assay and Sybr Green staining.  
B: The extent of DNA damage in wild type MEFs exposed to various doses of etoposide 
(VP16, squares) or H2O2 (circles) was measured by the comet assay as reported under 
Materials and Methods. C:  WT and Fe65 KO MEFs (cell lines KO3, KO8, KO9) were 
exposed to 15 μM etoposide or 10 μM H2O2 for one hour; thereafter the extent of DNA 
damage was measured by the comet assay. Standard error is reported for each point. 
15 µM etoposide 60 min.  
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2. Fe65 knock down (KD) cells have the same phenotype of  KO MEFs 
 
To confirm the phenotype observed in Fe65 KO MEFs we analyzed the sensitivity to 
genotoxic stress in other cellular systems in which Fe65 knockdown was obtained by RNA 
interference strategy. In NIH3T3 cells Fe65 expression was transiently suppressed by 
transfecting a shRNA-encoding vector targeting Fe65. A non silencing (ns) shRNA was 
transfected in control cells. As shown in figure 7 the western blot analysis with a specific 
Fe65 antibody, revealed that Fe65 protein level was reduced of about 80% compared to 
non silencing transfected cells. These cells were exposed to 20 µM etoposide for 1 hour at 
37° C and analyzed by Comet Assay.  
As shown in the graph, the tail moment of NIH3T3 knocked down cells is significantly 
higher than NIH3T3 non silencig transfected cell similar to what observed in Fe65 KO 
MEFs. We performed the same experiment in Neuro2A cells (N2A) in which the 
suppression of Fe65 was obtained by transfecting a pool of Fe65 specific siRNAs. Also in 
this case the western blot analysis shows an 80% reduction of Fe65 protein level compared 
to non silencing siRNA transfected cells. The knock down of Fe65 in N2A cells exposed to 
etoposide, leads to high level of damaged DNA compared to control cells (Figure 7) 
confirming that the absence of Fe65 in different cellular system results in high 










Figure 7: Suppression of Fe65 by RNA interference results in the same 














NIH3T3 or N2A cells were transfected with an shRNA-encoding vector or with siRNAs 
targeting Fe65, respectively. Western blot analysis demonstrated that the decrease of Fe65 
levels due to RNAi was of about 80%, compared to cells transfected with non silencing 
(ns) shRNA or siRNA. These cells were exposed to 20 µM etoposide for 1 hour and 
analyzed by Comet assay as described under Materials and Methods. The results obtained 
in NIH and N2A KD cells are compared to those obtained in Fe65 null MEFs exposed to 
20 µM VP16. A minimum of 50 cells per experiment were analyzed. All the experiments 
were done in triplicate. 
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3. Fe65 should be present in the nucleus to rescue the hypersensitivity of 
Fe65 KO MEFs to genotoxic stress 
 
It was well demonstrated that the overexpression of Fe65 in different cell lines is 
accompanied by the accumulation of the protein in the nucleus and APP functions as an 
extranuclear anchor preventing Fe65 nuclear translocation (Cao and Sudhof 2001) 
(Minopoli, de Candia et al. 2001). Indeed, when overexpressed alone, Fe65 accumulates in 
the nucleus. Furthermore, the C-terminal fragment of APP resulting from the cleavage 
catalyzed by γ-secretase was found in the nucleus associated with Fe65 (Kimberly, Zheng 
et al. 2001). These observations led to the hypothesis that the processing of APP could be 
involved in the mechanism regulating Fe65 availability in the nucleus. On the other hand, 
APP cytodomain is phosphorylated at Thr668 and this phosphorylation decreases the 
affinity of APP for Fe65 (Nakaya and Suzuki 2006), thus suggesting a second mechanism 
to regulate the nuclear availability of Fe65. Therefore, we addressed the question of 
whether the phenotype we observed in the Fe65 KO MEFs is related to Fe65 functions 
requiring its presence in the nucleus. To test this point we generated two expression 
vectors encoding Fe65 fused at the C-terminus to the nuclear export signal of the MAPKK 
or Fe65 fused to a mutated, non functional, version of this NES, as previously described in 
ref. 27. Moreover both fusion proteins were cloned in frame at the C-terminus with the 
myc tag sequence. Figure 8A shows the imminostaining with an anti-myc monoclonal 
antibody in cells overexpressing Fe65-NES and Fe65-mutNES. As expected the Fe65 
fused to the nuclear export signal accumulates in the cytoplasm and is mostly excluded 
from the nucleus, whereas the mutant NES sequence allows Fe65 nuclear accumulation. 
Fe65 KO MEFs transfected with the two recombinant proteins or with a vector encoding 
the Fe65 protein fused to the C-terminus with the myc  tag sequence were exposed to 
20µM etoposide and subjected to Comet Assay. 
The count of cells with the tail shows that transfection of the Fe65-NES protein was unable 
to rescue of the phenotype of KO MEFs, while the Fe65 fused to the mutant form of the 
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NES had the same effect as the wt Fe65-myc fusion protein (Figure 8 B) thus suggesting 


























Figure 8: Nuclear Fe65 is needed to rescue the phenotype of Fe65 KO 









Wild type and Fe65 KO MEFs were transfected with empty vector(mock) or with vectors 
encoding wt Fe65 or Fe65 fused to the nuclear export signal of MAPK (Fe65-NES) or 
Fe65 fused to a mutated non-functional version of the NES (Fe65-NESm). Anti-myc 
immunostaining (A) shows the cellular localization of the two recombinant proteins. 36 
hours after transfection, the cells were exposed to 15 μM etoposide for one hour and DNA 
damage was measured by comet assay (B). Expression level of transfected recombinant 
proteins is shown. Standard deviation is reported for each point. The asterisks indicate that 
the mean values are significantly different (p<0.01) from that of mock transfected cells. 
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4. Fe65 KO and KD cells show higher level of phosphorylated H2AX and 
p53 under genotoxic stress condition 
 
 
Comet assay analysis showed that the absence of Fe65 in different cellular systems leads to 
high sensitivity to DNA damage induced by genotoxic agents like VP16 or H2O2. 
To confirm this phenotype we analyzed the amount of phosphorylated H2AX histone and 
p53 upon low doses of etoposide treatment in Fe65 KO MEFs. Indeed both protein are 
early marker of DNA damage response since they are rapidly phosphotylated on specific 
residues by the serin/ threonine kinase ATM. We performed a Western Blot analysis with 
an antibody that specifically recognize phosphorylated H2AX on serin-139 (known as γ-
H2AX) on total protein extracts obtained from Fe65 KO and WT MEFs. As shown in 
figure 9A γ-H2AX was undetectable in non treated or DMSO treated WT MEFs, whereas 
the exposure to etoposide resulted in γ-H2AX accumulation. The amount of γ-H2AX is 
higher in KO than in WT MEFs after etoposide treatment. Moreover a little amount of γ-
H2AX was detectable also in non treated or DMSO exposed Fe65 KO MEFs thus 
confirming that the absence of Fe65 leads to high sensitivity to DNA damage. As shown in 
figure 4B also the phosphorylation of p53 on serin15 residue was higher in KO than in WT 
MEFs as a consequence of a stronger DNA damage response, and according to literature 
this modification leads to the accumulation of the protein as shown by the Western Blot of 
total p53. γ-H2AX is a very well known marker of damaged DNA since it accumulates in 
specific foci representing DNA double strand breaks. We measured the amount of γ-H2AX 
upon etoposide treatments (20 µM and 40 µM for 1 hour) in NIH3T3 cells and N2A cells 
in which Fe65 was knocked down as described before. As shown in figure 9 B and C in 
both cell lines the absence of Fe65 leaded to stronger phosphorylation of H2AX histone 
supporting the idea that the number of etoposide induced double strand breaks is higher in 
KD than in WT cells.  
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Figure 9: Fe65 KO and KD cells show stronger activation of H2AX and 
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A : Wild type and KO cells were exposed to 15 μM etoposide and their sensitivity to DNA 
damage was explored by measuring γ-H2AX (ser-139) and phospho-p53 (ser15) and the 
accumulation of total p53, as indicated. The Western blot refers to the experiment made 
with extracts from KO9 MEF line; extracts from two other lines gave the same results. 100 
µg of total protein extract were loaded per line. B and C : The phosphorylated form of 
histone H2AX (γ-H2AX) was measured by Western blot analysis in NIH 3T3 cells 
transfected with non silencing (ns) or Fe65 targeting shRNA and in N2A cells transfected 
with an siRNA targeting Fe65 or with non silencing (ns) siRNA as a control. Cells were 
exposed to two different concentration of VP16 ( 20 and 40 µM)  for 1 h.  









sh    ns     sh  ns 
40µM 20µM 
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5. ATM activation and NBS phosphorylation seem to be normal in Fe65 
KO MEFs upon DNA damage induction 
 
 
It is well known that generation of DSBs results in intermolecular modification within 
ATM dimers that leads to their activation via autophosphorylation of Ser-1981. 
Intermolecular phosphorylation subsequently triggers dimer dissociation, and the free 
monomers can phosphorylate several nuclear proteins for recruitment of DNA damage 
response proteins, including the MRN complex (Lukas, Falck et al. 2003). Considering that 
histone H2AX is, possibly, the first protein that is phosphorylated by ATM but also by 
other members of the ATM family (DNA-PK and possibly ATR), we decide to evaluate 
the phosphorylation of ATM in our KO MEFs upon etoposide treatment by Western Blot 
analysis using a ser-1981 phospho specific antibody. As shown in figure 10 the 
phosphorylation of ATM occurred normally in Fe65 KO MEFs compaired to WT 
suggesting that the upstream events during DNA damage response were unaffected in the 
absence of Fe65. 
To further investigate the proper activation of ATM we analyzed the phosphorylation of 
NBS1 that is one of the ATM downstream target phosphorylated in response to DSB-
inducing agents (Wu, Ranganathan et al. 2000) (Gatei, Young et al. 2000). NBS1 is 
recruited to damage sites by binding to MRE11 at the C-terminus in an ATM-independent 
manner, and then recruits/retains the MRN complex by binding to H2AX at the N-terminus 
in an ATM-dependent manner. The Western Blot with as anti-NBS antibody (figure 10) 
shows that the phosphorylation of NBS occurred properly in Fe65 KO MEFs upon 
etoposide treatment as demonstrated by the band migrating slower than unphosphorylated 





Figure 10: ATM activation and NBS phosphorylation are apparently 













The cell response to genotoxic stress was analyzed in wt and Fe65 KO MEFs exposed to 
40 μM etoposide by exploring the activation of ATM; active, autophosphorylated ATM 
(arrow) was analyzed by western blotting with anti-phospho-ATM (ser-1981) of the 
indicated extracts from untreated, DMSO- or etoposide-treated cells. Phosphorylation of 
NBS, one of the substrates of ATM, was analyzed by western blotting of the same extracts: 





6. Effects of DNA damage in Fe65 KO mice 
 
The differences observed between wild type and Fe65 KO MEFs could imply an abnormal 
response of Fe65 KO mice to DNA damage. Therefore, we analyzed the sensitivity of our 
KO mice to X-ray-induced DNA damage. KO male mice of 3 months of age and normal 
mice, sex and age matched and belonging to the same litter, were exposed to non-fatal, low 
doses (0.5and 1 Gy) of ionizing radiations. As shown in Figure 11, 2.5 hours after the 
exposure to ionizing radiations brain extracts from Fe65 KO mice showed higher levels of 
phosphorylated γ-H2AX and a higher p53 accumulation compared to those of wild type 
mice. The latter are clear signs of the high sensitivity of Fe65 KO mice to genotoxic stress, 


















Figure 11: Fe65 knock out mice are highly sensitive to DNA damage. 
 




























WT andFe65 KO mice were exposed to 0.5 and 1 Gy of X rays as described under 
Materials and Methods. 2.5 hours after irradiation the animals were sacrificed and brain 
extracts were analyzed by western blotting with anti-γ-H2AX histone or with anti p53 
antibodies. Myosin heavy chain is used as a control of load. Controls experiments from 





7. Fe65 associates with intact and damaged chromatin and undergoes 
rapid phosphorylation in response to DNA damage 
 
The findings that the absence of Fe65 leads to hypersensitivity to DNA damage and that it  
should be present in the nucleus to rescue this phenotype suggested us to investigate the 
possibility that Fe65 is a chromatin bound protein. Therefore we analyzed Fe65 association 
with chromatin at a global genomic level both in basal conditions and in presence of DNA 
damage. To this aim, we immunoprecipitated crosslinked chromatin from N2A cells with an 
histone H3 antibody. This H3 immunoprecipitated chromatin, roughly representing the whole 
chromatin, was de-crosslinked and analyzed by western blot for the presence of Fe65. Figure 
12A shows that Fe65 is indeed associated with intact chromatin and that this association was 
only slightly increased upon genotoxic stress induced by etoposide. Moreover the western blot 
revealed that the protein migration was slower in the sample exposed for 10 minutes to 
etoposide than non treated sample probably as a consequence of protein phosphorylation. To 
further investigate this possibility, we monitored nuclear Fe65 at various times after the 
exposure of wild type MEFs to 40 μM etoposide (figure 12B). We previously 
demonstrated that our polyclonal antibody against Fe65 recognizes several bands in 
nuclear extracts, the slowest migrating ones are erased by the alkaline phosphatase 
treatment (Zambrano, Minopoli et al. 1998). The etoposide treatment induced a rapid 
modification of the pattern of the Fe65 bands after 5 and 10 minutes. Thereafter, the basal 
pattern was restored (20 min) and remained unchanged for several hours. The amount of 
cytosolic Fe65 was not affected by the etoposide treatment. We performed the same 
experiment in NIH-3T3 cells exposed to the radiomimetic agent Neocarzinostatin (NCS). 
As shown in figure 12C the exposure of cells to NCS for 10 minutes resulted in the 
accumulation of a band  with slower migration than non treated cells, supporting the idea 
that Fe65 phosphorylation is an early event during DNA damage response. The association 
to chromatin and the rapid modification of Fe65 as a consequence of the exposure of the 
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cells to DNA damaging agents suggest its involvement in the early steps of the cellular 


























Figure 12: Endogenous Fe65 associates with chromatin and undergoes 


























A: N2A cells were treated or not with 100 μM etoposide for the indicated times. 
Crosslinked chromatin was immunoprecipitated with histone H3 antibody. De-crosslinked 
chromatin was analyzed by western blot with Fe65 antibody. Input indicates the non 
immunoprecipitated crosslinked extract. B: Normal MEFs were exposed to 40 μM 
etoposide for the indicated times. Nuclear and cytosolic extracts were prepared at the 
indicated intervals and analyzed by western blot with anti-Fe65 antibody (L12 serum 
1:2000). Lamin B and actin were used as control of loading. C: NIH3T3 cells were 
exposed to neocarzinostatin (NCS) 0.5 µg/ml for 10 minutes. Nuclear extracts were 





 We know that after sequential proteolytic processing of membrane-bound APP and release 
of AICD into the cytoplasm, Fe65 can translocate to the nucleus to participate in gene 
transcription events. This role is further mediated by the interactions of Fe65 PTB1 with 
the transcription factors CP2/LSF/LBP1 and Tip60 and the WW domain with the 
nucleosome assembly factor SET although none of proposed Fe65 target genes have yet 
been confirmed. The finding that Fe65 is a chromatin bound protein suggested us to 
explore the possibility that its association with chromatin preferentially occurs at the 
genomic regions that are highly trascribed. To explore this possibility we analyzed in 
NIH3T3 cells, the association of Fe65 with three random genomic loci, i.e. those of RNA 
polymerase II that is a constitutive gene, albumin that is a tissue specific gene and glutathione-
S-transferase that is an inducible gene performing Chromatin Immunoprecipitation (ChIP) 
experiments. To this aim chromatin from NIH-3T3 cells was immunoprecipitated with an anti-
Fe65 antibody or control IgG and immunoprecipitated chromatin was amplified with three 
different oligo pairs surrounding the transcriptional start site, the upstream and the downstream 
regions of each locus. As shown in figure 13 the Fe65 antibody was able to immunoprecipitate 
the endogenous protein at each locus. Moreover this association seems to be independent from 
transcriptional status of chromatin since Fe65 bound to the same extent the analyzed 






































Chromatin from NIH3T3 cells was immunoprecipitated with Fe65 antibody (black bars) or 
control IgG (grey bars) and amplified with the oligonucleotide pairs reported in SI Table 
III of (materials and methods) , to explore the presence of Fe65 on three genomic loci. The 
oligonucleotides were designed to amplify regions of the RNA polymerase II, serum 
albumin and glutathione-Stransferase genes close to their start sites and at the indicated 






8. Fe65 association with chromatin determines its degree of condensation.  
The finding that the absence of Fe65 rendered the cells more vulnerable to DNA lesions and 
that Fe65 associated with chromatin both in basal and under genotoxic stress conditions, 
suggested us to explore its possible involvement in chromatin condensation state. To this aim 
we analyzed the accessibility of chromatin to micrococcal nuclease digestion in Fe65 KO and 
KD cells compared to WT. We found that chromatin from Fe65 KO MEFs or Fe65 KD cells 
was more accessible to micrococcal nuclease digestion, than chromatin from wt cells 
(figure14), thus demonstrating that Fe65 suppression leads to a significant degree of chromatin 
de-condensation. This phenotype was rescued by Fe65 re-expression in KO MEFs (figure 
15A). 
Moreover Fe65 overexpression in NIH3T3 cells results in highly condensated state (figure 
15B) since chromatin from NIH3T3 overexpressing cells was quite completely undigested 
even after 10 minutes of incubation with micrococcal nuclease. These data revealed that the 
association of Fe65 with chromatin is functionally relevant since it determines the degree of 































Chromatin from the indicated cell lines, in which Fe65 was suppressed by gene KO or by 
RNA interference, was digested with 2 mM micrococcal nuclease for the indicated times. 
Digested DNA was examined by agarose gel electrophoresis. Fe65 KO or KD result in the 





Figure 15:Fe65 expression in KO cells restore the chromatin 


















A: Retroviral-directed reexpression of wt Fe65 in KO MEFs restored the normal cleavage 
pattern in micrococcal nuclease assay as demonstrated by the absence of small bands even 
after 8 minutes of nuclease digestion. 
B: Chromatin from Fe65 overexpressing NIH3T3 was resistant to micrococcal nuclease 





9. Fe65 mutants lacking the WW and the PTB1 domains or carrying 
C655F point mutation are unable to rescue the Fe65 KO MEFs 
phenotype 
 
Fe65 has the three protein-protein interaction domains interacting with several nuclear 
proteins. Among these two lingands are involved in chromatin remodelling functions. 
Indeed Fe65 interacts with the nucleosome assembly protein SET through a region that 
partially overlaps the WW domain and with the histone acetyl-transferase Tip60 and the 
transcription factor LSF through the PTB1 domain. Our findings on Fe65 involvement in 
regulation of chromatin state strongly support a possible mechanism involving SET and 
Tip60 proteins. Moreover Fe65 interacts with APP or AICD through the PTB2 domain. To 
explore the possible involvement of these known partners in the Fe65 nuclear function 
responsible for the phenotype observed in KO and KD cells, we cloned in the pBabe 
retroviral vector (see Materials and Methods) several mutants carrying deletion or point 
mutations in the three domains of the protein. In figure 16A the structural organization of 
wild type protein and its mutants is shown. The ΔupWW mutant completely loses the N-
terminus region of the protein until aminoacid residue 253.  
This region is not involved in any known interaction but it contains a peculiar acidic region 
possibly involved in the association with chromatin.  
The ΔWW loses the entire WW domain starting from aminoacid residue 291. The absence 
of WW domain has a profound effect on the protein since this mutant is unable to reach the 
nucleus. Moreover it is unable to interact with SET protein. The ΔPTB1 mutant loses the 
region of the PTB1 domain between aminoacid 451-510 thus abolishing the interaction 
with Tip60.  
The ΔPTB2 mutant entirely loses the PTB2 domain that is involved in the APP/AICD 
binding. We generated also two mutants carrying specific point mutations. The first 
contains a triple mutation in the WW domain substituting the YYW sequence with AAA. 
This mutation specifically abolishes the interaction with SET protein and the 
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transactivation property of the protein. The second contains a single point mutation in the 
PTB2 domain (C655F) that specifically abolishes the interaction with APP and its 
paralogues APLP1 and APLP2. 
The expression level of wild type protein and its mutants were analyzed by western blot   
in Fe65 KO MEFs upon retroviral infection (figure 16B) using an anti-myc tag antibody or 
an antibody recognizing an epitope in the WW domain. Infected cells were also analyzed 
by immunostaining with an anti-myc antibody to evaluate the cellular localization of each 
Fe65 mutant. As shown in figure 17A, the ΔPTB1, ΔPTB2 and the ΔupWW mutants 
showed the same cellular localization of the wild type protein since they accumulated in 
the nucleus upon overexpression. Also the C655F and the YYW?AAA mutants showed a 
proper nuclear localization thus suggesting that the loss of interaction with SET, Tip60 or 
APP/AICD do not alter the Fe65 nuclear localization. As expected, the ΔWW mutant is 
unable to reach the nucleus and accumulates in the cytoplasm confirming that this region is 
necessary for protein nuclear localization. We performed a rescue experiment in Fe65 KO 
MEFs expressing each mutant protein. To this aim infected cells were exposed to 20µM 
etoposide and analyzed by comet assay counting the number of cells with the tail (figure 
17B). As previously shown the wild type protein was able to rescue the phenotype whereas 
the protein fused to the nuclear export signal did not. As expected also the ΔWW mutant 
was unable to rescue the phenotype being excluded from the nucleus. The ΔupWW and the 
ΔPTB2 mutants rescued the phenotype with the same extent of the wild type protein. 
Finally, despite their proper nuclear localization, the ΔPTB1, the YYW?AAA and the 
C655F mutants were unable to rescue the phenotype suggesting that Fe65 interaction with 
Tip60, SET and APP/AICD is necessary for its nuclear function in DNA damage response. 
Interestingly the C655F mutant lacking the interaction with APP/AICD was unable to 
rescue the phenotype although the mutant lacking the entire PTB2 domain (ΔPTB2) 
behaved like the wild type protein.      
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A: Structural organization of wild type Fe65 protein and its mutants carrying specific 
deletions or point mutations. The number of aminoacid residues corresponding to deleted 
regions or mutated residues refers to rattus protein sequence. B: Western blots of Fe65 KO 
MEFs after infection with indicated Fe65 mutants were carried out with an antibody 




Figure 17: Dissection of Fe65 interaction domains necessary to rescue the 



































A : Fe65 KO MEFs were infected with corresponding mutants as reported under Materials 
and Methods  and stained with an anti-myc tag antibody to  reveal their cellular 
localization. B:  Fe65 KO MEFs expressing indicated proteins and exposed to 20µM VP16 
or to DMSO as a control were analyzed by comet assay counting the number of cells with 
the tail. A minimum of 50 cells per experiment were analyzed. All the experiments were 




10. Generation of the DR-GFP/ISce-I-ER system to study Fe65 
involvement in chromatin remodelling during DNA repair   
 
 
The finding that the Fe65 mutant unable to bind Tip60 (ΔPTB1) failed to rescue the high 
sensitivity to DNA damage observed in KO and KD cells, suggested us to focus on the 
possible involvement of Fe65/Tip60 complex in the cellular response to DNA damage. 
Indeed Tip60 is a well studied histone acetyl transferase involved in many cellular 
processes including chromatin remodelling during DNA repair of double strand breaks 
(DSBs). It has been sown that the NuA4 complex containing Tip60 and its cofactor 
TRRAP is rapidly recruited at DSBs during DNA repair to drive the acetylation of histone 
H4 in the surrounding region. Tip60 driven histone acetylation results in local chromatin 
decondensation that favours the loading of DNA repair machinery (Murr, Loizou et al. 
2006). To analyze the possible involvement of Fe65 in Tip60 mediated chromatin 
remodelling during DNA damage response, we exploited the DRGFP/I-SceI experimental 
system (Richardson, Elliott et al. 1999) (see figure 18A). To this aim, we generated clones 
of NIH3T3 cells stably transfected with a DNA construct (DR-GFP) containing two non-
functional GFPs. The upstream (5’) GFP is under the control of the β-actin gene promoter 
and contains a single recognition site for the I-SceI endonuclease. Considering that no I-
SceI sites are present in mammalian genomes, the expression of this enzyme results in 
generation of single DNA DSB only at DR-GFP sites (29, and figure 18A). We also 
generated an I-SceI-ER expression vector, in which the ISceI cDNA is fused in frame with 
the cDNA fragment encoding the hormone-binding site of the estrogen receptor alpha 
(ERα). The double stable clones NIH-GS bearing DR-GFP and I-SceI-ER were pooled and 
treated with 4-OH tamoxifen. Figure 18B shows the nuclear translocation of ISce-I-ER 
fusion protein upon 4-OH tamoxifen treatment. We performed chromatin 
immunoprecipitation experiments in our NIH-GS cells to evaluate Tip60/TRRAP 
recruitment and histone H4 acetylation upon I-SceI-ER driven DSBs generation, 
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A: 5’ GFP sequence was cleaved by I-SceI-ER upon the exposure of the NIH-GS cells to 
1μM 4-Hydroxytamoxifen (tamoxifen) for 6 hours. Upon the cleavage, Tip60-TRRAP-
containing complex was recruited at the DNA and histone H4 was acetylated by Tip60. 
Gene conversion events are able to repair the double strand break induced by I-SceI by 
using the downstream 3′ GFP as donor that allow GFP expression.B: Immunostaining of 
NIH-GS cells with an anti-ERα monoclonal antibody that reveals the cellular localization 
of the ISce-I-ER fusion protein before and after 4-OH-tamoxifen treatment. 
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11. Fe65 suppression prevents the recruitment of Tip60-TRRAP at DNA 
double strand breaks 
 
In agreement with that previously observed by others (Murr, Loizou et al. 2006), the 
cleavage induced by I-SceI-ER in NIH-GS cells resulted in the recruitment of Tip60 to the 
site of DNA damage. In fact, ChIP experiments with Tip60 antibody showed a significant 
enrichment of Tip60 at the 5’ GFP site upon the induction of I-SceI-ER by tamoxifen. This 
enrichment was clearly detectable with oligonucleotide pairs amplifying DNA at 0.5 and 2 
kb downstream of the cleavage site, but not with the control oligonucleotide pair targeting 
the region 10 kb downstream of the DSB (figure 19A). Interestingly, in cells where Fe65 
was knocked down Tip60 recruitment to DSB was strongly decreased (figure 19A). 
Similar to Tip60, its partner TRRAP was recruited to DNA breaks in wt cells. Fe65 KD 
resulted again in a significant decrease of TRRAP recruitment (figure 19B). As a 
consequence of the impairment of Tip60-TRRAP recruitment to DNA strand breaks, ChIP 
experiments with an anti-acetyl-H4 antibody demonstrated that while in wt cells I-SceI-
driven cleavage induced the histone H4 acetylation at the I-SceI site, the concomitant 












Figure 19: Fe65 suppression affects Tip60 and TRRAP recruitment at 
DNA double strand breaks. 
 
 































Fe65 knockdown is accompanied by a decreased recruitment of Tip60 at DNA double 
strand breaks. NIH-GS cells, stably transfected with the inducible form of I-SceI-ER 
restriction enzyme and with DR-GFP construct (see Materials and Methods) bearing a 
single I-SceI cleavage site, were treated with 1 µM tamoxifen for 6 hours. ChIP was 
performed with Tip60 antibody (+) or control IgG (-). Immunoprecipitated chromatin was 
analyzed by real time PCR using three oligonucleotide pairs located at approximately 0.5, 
2 and 10 Kb downstream of the I-SceI cleavage site. *: p<0.01. (C) TRRAP recruitment at 
DNA break induced by I-SceI was analyzed as described in panel B, by 
immunoprecipitating chromatin with TRRAP antibody.  
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Chromatin, immunoprecipitated with an antibody recognizing acetylated histone H4, was 
analyzed in Fe65 KD NIH-GS cells before and after 4OH-tamoxifen induction of ISce-I-
ER amplifying DNA regions located at approximately 0.5, 2 and 10 Kb downstream of the 





12. The ΔPTB1 mutant overexpression decreases Tip60 recruitment and 
histone H4 acetylation at DNA breaks.  
 
ChIP experiments in NIH-GS cells demonstrated that Fe65 is necessary for proper 
recruitment of Tip60 and its cofactor TRRAP at DNA double strand break suggesting that 
Tip60 could directly interact with the chromatin associated Fe65 in early steps of DNA 
repair. To further explore the role of Fe65/Tip60 interaction during DNA repair we 
analyzed the loading of Tip60 at DNA double stand break in NIH-GS cells expressing the 
ΔPTB1 mutant by chromatin immunoprecipitation experiments. As shown in figure 21A 
the expression of Δ-PTB1 mutant had a dominant negative effect strongly reducing Tip60 
loading both at 0.5 and 2 Kb downstream regions. Accordingly H4 acetylation level was 
strongly reduced in ΔPTB1 expressing NIH-GS cells compared to mock or wild type Fe65 

















Figure 21: The overexpression of ΔPTB1 mutant impairs Tip60 loading 

































A: NIH-GS cells were transfected with Δ-PTB1 expression vector. After 24 hours, they 
were treated with 1 µM tamoxifen or with vehicle (-) for 6 hours. ChIP was performed 
with Tip60 antibody or control IgG. Immunoprecipitated chromatin was analyzed by Real 
time PCR using three oligonucleotide pairs located at approximately 0.5, 2 and 10 Kb 
away from I-SceI cleavage site. *: p<0.01 Overexpression of the Fe65 mutant Δ-PTB1 
decreases histone H4 acetylation at DNA breaks. NIH-GS cells were transfected with the 
indicated vector. ChIP experiments were performed as described in panel A.  **: p<0.05 
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13. The ΔPTB1 dominant negative effect depends on its interaction with 
chromatin 
 
To explain the dominat negative effect of ΔPTB1 mutant on Tip60 loading and 
consequently on histone H4 acetylation at DNA double strand break, we analyzed the 
capability of this mutant to interact with intact and damaged chromatin using NIH-GS 
cellular system. We had previously demonstrated that endogenous Fe65 is widely 
associated with chromatin both in basal conditions and upon DNA damage induction 
(figure 12A and figure 13). To confirm these data we performed ChIP experiments in NIH-
GS cells treated with vehicle or 4-OH tamixifen for 6 hours. Chromatin was 
immunoprecipitated with an anti-Fe65 antibody or control IgG and immunprecipitated 
DNA was amplified by Real time PCR with the three oligo pairs described before. The 
endogenous Fe65 associated with chromatin in the regions surrounding the ISce-I site (0.5 
and 2 Kb downstream regions). Moreover Fe65 was still detected 10 Kb downstream from 
I-SceI site confirming that it is widely associated with chromatin.  
I-SceI-ER induction of double strand breaks did not alter the amount of associated protein 
at three analyzed sites confirming that Fe65 interacts both with intact and damaged 
chromatin (figure 22A).  
ChIP experiments were carried out in NIH-GS cells transfected with the Fe65-myc 
encoding vector in which the wild type protein is fused to the myc tag. Chromatin was 
immunoprecipitated with an anti-myc tag antibody or control IgG  and amplified with the 
three oligo pairs described before (figure 22B).  
Similar to the endogenous protein, ectopically expressed Fe65-myc fusion protein was still 
able to interact with intact and damaged chromatin at three analyzed sites. Chromatin from 
NIH-GS cells expressing the ΔPTB1-myc mutant was immunoprecipitated with an anti 
myc antibody or control IgG. The amplification of immunoprecipitated chromatin with the 
three oligo pairs described before, revealed that the ΔPTB1 mutant was still able to interact 
with chromatin (figure 22C) thus explaining its dominant negative effect. Indeed the 
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ΔPTB1 mutant associated with chromatin could compete with the endogenous protein for 
the binding of some other partners of Fe65, which may be necessary for Fe65 proper 


























Figure 22: The ΔPTB1 mutant is able to interact with intact and 






















A: Chromatin form NIH-GS cells were treated with 1 µM tamoxifen or with vehicle (-) for 
6 hours. ChIP was performed with an Fe65 antibody or control IgG. Immunoprecipitated 
chromatin was analyzed by Real time PCR using three oligonucleotide pairs located at 
approximately 0.5, 2 and 10 Kb away from I-SceI cleavage site. B: NIH-GS cells were 
transfected with an expression vector encoding the wild type Fe65 fused to the C-terminus 
with the myc tag. 48 hours upon transfection cells were treated with tamoxifen as in panel 
A and ChIP was carried out with an anti myc tag antibody or control IgG. 
Immunaprecipitated chromatin was amplified as in panel A. C: NIH-GS cells were 
transfected with  an expression vector encoding the ΔPTB1 mutant fused to the C-terminus 
with the myc tag. 48 hours upon transfection cells were treatedwith tamoxifen as in panel 
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A and B. ChIP was carried out with an anti myc tag antibody or control IgG. 
Immunaprecipitated chromatin was amplified as in panel A and B. 
 
  
14. Fe65 is necessary for efficient DNA repair 
Chromatin immunoprecipitation experiments in NIH-GS cells clearly demonstrated the 
relevance of Fe65 in Tip60/TRRAP loading at DNA double stand breaks. As a 
consequence of Tip60/TRRAP decreased loading, acetylation of histone H4 was impaired 
in Fe65 KD cells or in ΔPTB1 expressing cells compaired to wild type.  
To address the relevance of the Fe65 in DSB repair we measured the efficiency of repair in 
the same NIH-GS experimental system described before. These cells are stably transfected 
with DR-GFP and I-SceI-ER. The DR-GFP DNA fragment contains two non-functional 
GFPs. Indeed the 5’ GFP gene in the DR-GFP sequence is under the control of the β-actin 
gene promoter, but it is mutated in order to generate two in-frame stop codons that 
terminate translation, thereby inactivating the GFP gene. The downstream (3′) GFP is 
inactivated by upstream and downstream truncations, leaving only about 500 bp of the 
GFP sequence (see figure 18A).  
When NIH-GS cells were treated with tamoxifen, the I-SceI-ER nuclear translocation 
results in DSBs generation. One possibility to repair these lesions is the homologous 
recombination repair that in this system induces intra chromosomal gene conversion 
leading to the reactivation of the 5’ GFP gene. Indeed when the DSB is correctly repaired 
the frame of 5’ GFP gene is restored allowing GFP expression. Thereby the extent of repair 
by homologous recombination was measured by counting GFP positive cells by FACS (see 
figure 23). In NIH-GS cells treated with 4-OH-tamoxifen the percentage of GFP positive 
analyzed 48 hours upon treatment, was about 3.5% whereas only few cells in the control 
expressed GFP. Under these conditions, we analyzed the effect of Fe65 KD on DNA repair 
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efficiency. To this aim NIH-GS cells were transfected with a pool of specific Fe65 siRNA 
or with non silencing siRNA as control. We measured the number of GFP positive cells by 
FACS analysis 48 hours after 4-OH tamoxifen exposure. As shown in figure 24 the Fe65 
KD is accompanied by a significant decrease in GFP positive cells, thus clearly indicating 
that Fe65 KD reduced the efficiency of DNA repair. In agreement with ChIP experiments, 
a significant reduction of repair efficiency was also observed by transfecting NIH-GS cells 
the cells with the Δ-PTB1 mutant, thus confirming the dominant negative effect of this 
















































The upstream 5’ GFP gene of DR-GFP construct, is under the control of the β-actin gene 
promoter, but it contains two in-frame stop codons that terminate translation, thereby 
inactivating the gene. The recombination event leads to the reactivation of the GFP gene, 
because the donor 3′ GFP does not contain the above-mentioned stop codons. Therefore, a 
functional GFP is expressed in the cells where a successful repair takes place and the 
extent of repair can be measured by counting GFP positive cells by FACS. Two examples 
of FACS analyses are reported: in NIH-GS cells treated with vehicle the number of GFP 
positive cells was of about 0.5%, while it was of about 3.5% in the cells where I-SceI-ER 

































DNA repair efficiency in NIH-GS cells was measured by counting the percentage of GFP-
positive cells 48 hours after the exposure of the cells to tamoxifen, which activates I-SceI 
ER. Representative FACS output of one experiment is shown: the upper panels refer to 
cells transfected with non-silencing control siRNA or Fe65 targeting siRNA and exposed 
to vehicle. The lower panels show the results obtained in cells treated with tamoxifen. The 
histogram reports the mean values of three independent experiments. Grey bars indicate 
the mean values obtained in the presence of vehicle. The difference between the two black 
bars is significant with a p< 0.01. 
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A: DNA repair efficiency in NIH-GS cells transfected with Δ-PTB1 was measured by 
counting the percentage of GFP positive cells, 48 hours after the exposure of cells to 
tamoxifen or to vehicle for 6 hours. Representative FACS outputs of one experiment are 
shown: the upper panels refer to cells exposed for 6 hours to vehicle. The lower panels 
show the results obtained in cells treated with tamoxifen. B: The histogram reports the 
mean values of three independent experiments. Grey bars indicate the mean values 
obtained in the presence of vehicle. The difference between the two black bars is 
significant with a p<0.01. C: Western blot analysis of ΔPTB1 expression in NIH-GS cells. 
Actin was used for control of loading.  
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15. APP processing is induced by genotoxic stress in a γ-secretase  
dependent manner 
 
The finding that Fe65 is a chromatin associated protein involved in Tip60 driven chromatin 
remodeling during DNA repair suggested us to explore the possibility that APP and its 
proteolitic processing could be involved in this nuclear function. Moreover we found that 
Fe65 undergoes rapid phosphorylation upon DNA damage induction suggesting that its 
phosphorylation could be the mechanism triggering NuA4 proper localization. Similar to 
Notch the final step of APP proteolitic processing involves the γ-secretase cleavage that 
generates the short C-terminal fragment AICD. Several data suggest that γ-secretase 
cleavage of APP could be a mechanism triggering the Fe65/AICD nuclear localization. We 
first analyzed the effect of etoposide treatment on APP proteolitic processing monitoring 
by western blot analysis the amount of the APP C-terminal fragments (CTF) derived from 
the cleavage of APP by α - or β-secretase, C83 and C99, respectively. To this aim we used 
an APP antibody recognizing the C-terminal region of the protein that is able to detect both 
APP holoprotein and its CTFs. As shown in figure 26A, in the wild type, untreated MEFs, 
only the C83 band is clearly visible accordingly with the notion that APP ectodomain 
shedding is mainly due to α-secretase cleavage. The treatment with 40 μM etoposide 
resulted in a drastic decrease of the APP-CTF amount within few minutes and returned to 
basal levels two hours later. The observed decrease suggested us a possible induction of γ-
secretase cleavage upon genotoxic stress induction. To asses this point we performed the 
same experiment in wild type MEFs pretreated with the γ-secretase inhibitor DAPT. As 
shown in figure 26B DAPT treatment prevents the decrease of APP-CTF clearly 
demonstating that it depends on the induction of γ-secretase. Furthermore, both APP and 
APP-CTF in cells pretreated with DAPT and exposed to etoposide seemed to accumulate 
up to levels higher than those present in cells treated only with DAPT. 
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APP and APP-CTF were analyzed by western blot in wild type MEFs used an antibody 
recognising an epitope in the C-terminal fragment of the protein (see Materials and 
Methods) A: Protein extracts were obtained from wild type MEFs exposed to 40µM 
etoposide for indicated time or to DMSO in control cells. 100µg of total protein extract 
was loaded per lane and tubulin was used for control of loading. The cartoon shows the 
APP-CTF stub in the membrane and the γ-secretase cleavage site (arrow).  
B: Protein extracts were obtained from wild type MEFs pretreated chronically with 2µM 
DAPT for 24 hours and then exposed to 40µM etoposide for indicated time or to DMSO in 
control cells. As in A tubulin was used for control of loading. The cartoon shows the APP 
oloprotein, the first cleavage site that determines the shedding of the ectodomain and the 
inhibition of γ-secretase site by DAPT treatment.                                                       
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These finding suggested a relationship between Fe65 modifications and the cleavage of the 
APP-CTF in response to DNA damage. To explore this point we analyzed the cleavage of 
APP-CTF in Fe65 KO MEFs. As shown in figure 27, in these cells the treatment with 
etoposide does not induce any changes in the amount of APP-CTF, thus further supporting 
that APP processing is dependent on Fe65 modification induced by genotoxic stress. 
Genotoxic stress induced activation of γ-secretase complex occurred with a little delay 
respect to Fe65 nuclear modification and Fe65 was necessary for the induction of γ-
secretase cleavage of APP in response to etoposide treatment. Moreover the Fe65 mutant 
unable to interact with APP (C655F) did not rescued the Fe65 KO MEFs phenotype (figure 
17B).  
These data suggest that Fe65/APP interaction could be a crucial event in Fe65 nucler 
function during DNA repair. 
 
16. The interaction with APP is required for Fe65 function in DNA repair 
 
To better explore the molecular mechanism involving APP in Fe65 nuclear function during 
DNA repair we analyzed the effect of C655F mutant expression in NIH-GS cells.  
Chromatin immunoprecipitation experiments in NIH-GS cells expressing C655F mutant 
demonstrated a strong decrease of Tip60 loading in the region surrounding the DSB (figure 
28A) compared to control cells.  
Accordingly the acetylation level of histone H4 was strongly reduced in C655F expressing 
cells (figure 28B). 
We further evaluated the effect of C655F mutant on DNA repair efficiency by FACS 
analysis counting the number of GFP positive cells (figure 29). As expected the expression 
of C655F mutant resulted in a strong dominant negative effect on DNA repair efficiency. 
These results suggest that the interaction with APP/AICD is necessary to allow Fe65 to 
adequately function during DNA repair. 
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Figure 27: Genotoxic stress induced γ-secretase cleavage of APP depends 

























APP-CTF were analysed by western blot with an anti APP C-terminal antibody in Fe65 
KO MEFs treated with etoposide at indicated time or with DMSO as control. 100µg of 











Figure 28: Fe65 mutant unable to bind APP shows a dominant negative 






































A: NIH-GS cells were transfected with C655F mutant or empty vector and exposed to 
tamoxifen as indicated. Chromatin was immunoprecipitated with an anti-Tip60 antibody 
and analyzed with the three oligo pairs described before. 
B: ChIP experiments were performed as described in A using an anti-acetyl histone H4 
 









    




























A: DNA repair efficiency in NIH-GS cells transfected with C655F mutant was measured 
by counting the percentage of GFP positive cells, 48 hours after the exposure of cells to 
tamoxifen or to vehicle for 6 hours. Representative FACS outputs of one experiment are 
shown: the upper panels refer to cells exposed for 6 hours to vehicle. The lower panels 
show the results obtained in cells treated with tamoxifen. B: The histogram reports the 
mean values of three independent experiments. Grey bars indicate the mean values 
obtained in the presence of vehicle. The difference between the two black bars is 
significant with a p<0.01. C: Western blot analysis of C655F mutant expression in NIH-GS 
cells. Actin was used for control of loading.  
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17. The dominant negative effect of C655F mutant depends on its 
inability to interact with chromatin. 
 
 
To better explore the mechanism by which the C655F mutant exerted a dominat nagative 
effect on DNA repair we analyzed the capability of this protein to interact with Tip60. To 
this aim we performed co-immunoprecipitation experiments in NIH3T3 cells expressing 
both the Tip60-HA fusion protein and Fe65-myc in control cells or both Tip60-HA and 
C655F mutant. Nuclear protein extract from these cells were immunoprecipitated with an 
anti-HA tag antibody and immunoprecipitated protein were analyzed by western blot with 
an anti-myc tag antibody. As shown in figure 30A the C655F mutant binds Tip60 with the 
same extent of wild type protein. This result suggested that Fe65 interaction with APP is 
dispensable for Fe65 proper binding to Tip60.  
Moreover, we analyzed the ability of C655F mutant to interact with chromatin before and 
after DNA damage induction in NIH-GS cellular system.  
NIH-GS cells expressing the C655F-myc protein were exposed for 6 hours to tamoxifen or 
control vehicle. Chromatin was immunoprecipitated with an anti-myc tag antibody or 
control IgG. The amplification of immunoprecipitated chromatin with the three oligo pairs 
located at respectively 0.5, 2 and 10 Kb from I-Sce-I site revealed that C655F mutant was 
unable to interact with both intact and damaged chromatin (figure 30C).  
These data suggested that C655F mutant exerts its dominat negative effect on DNA repair 








Figure 30: The dominant negative effect of C655F mutant depends on its 
inability to interact with chromatin. 
 
 























A: NIH3T3 cells were transfected with both Fe65-myc and Tip60-HA expression vectors 
or with both C655F-myc and Tip60-HA. Nuclear protein extract were obtained from these 
cells 48 hours upon transfection and immunoprecipitated with an anti-HA tag antibody or 
with control IgG. Immunoprecipitated protein were resolved by SDS page and analysed by 
western blot with an anti-myc tag antibody. B: Association of C655F mutant with 
chromatin was analyzed as in figure 12A. The experiment shown in the upper panel 
demonstrated that C655F mutant was not associated to chromatin either in cells treated 
(VP16) or not treated (DMSO) with 100 µM etoposide. The lower panel (re-blot of the 
filter shown in the upper panel) shows that endogenous Fe65 is associated with chromatin. 
C: ChIP experiments were carried out in NIH-GS cells expressing C655F-myc mutant as 
described in figure 21.  
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18. Fe65 interaction with APP is essential for its association with 
chromatin and in turn for its proper function in DNA repair. 
 
 
The finding that C655F mutant was unable to interact with chromatin suggested the 
possibility that Fe65 interaction with APP is necessary for its association with chromatin.  
To better explore this point we evaluated the effect of APP/APLP2 KD on Fe65 function in 
DNA repair. NIH-GS cells were transfected with non silencing siRNA (NS) or with two 
siRNAs targeting APP and it paralogue APLP2 respectively. 48 hours upon transfection 
the level of both proteins was strongly reduced in APP/APLP2 double knock down cells 
(DKD) compared to NS (figure 31A). We first evaluated in these cells the association of 
Fe65 with chromatin by ChIP experimets (figure 31B).  
APP/APLP2 KD abolished the association of Fe65 with chromatin at three analyzed sites 
thus clearly indicating that the interaction of Fe65 with APP/APLP2 is necessary to allow its 
association with chromatin. As expected the loading of Tip60 and TRRAP and the acetylation 
of histone H4 were drastically decreased in APP/APLP2 KD cells compared to non silencing 
cells (figure 32 A, B, C). Accordingly, DNA damage repair was less efficient in APP/APLP2 









































A: NIH-GS cells were transfected with non-silencing (NS) siRNA or with siRNAs 
targeting APP and APLP2 (double knock down; DKO). Western blot with APP or APLP2 
antibodies was performed 48 hours upon transfection. 
B: Chromatin from non silencing (NS) and APP/APLP2 knock down (KD) NIH-GS cells 








Figure 32: APP/APLP2 KD impairs the loading of NuA4 complex and 










































Chromatin immunoprecipitation experimets were carried out as described before, in 
APP/APLP2 KD NIH-GS cells using anti-Tip60 (A), anti-TRRAP (B) and anti-acetyl H4 
(C) antibodies. 
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A: DNA repair efficiency in NIH-GS cells transfected with both APP and APLP2 targeting 
siRNAs was measured by counting the percentage of GFP positive cells, 48 hours after the 
exposure of cells to tamoxifen or to vehicle for 6 hours. Representative FACS outputs of 
one experiment are shown: the upper panels refer to cells exposed for 6 hours to vehicle. 
The lower panels show the results obtained in cells treated with tamoxifen. B: The 
histogram reports the mean values of three independent experiments. Grey bars indicate 
the mean values obtained in the presence of vehicle. The difference between the two black 
bars is significant with a p<0.01.  
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DISCUSSION 
The phenotype of Fe65 KO cells and mice we observed at the beginning of my PhD project 
suggested us to explore the possible link between the function of this protein and the 
cellular machinery devoted to protect from and/or respond to DNA damages. Previous 
results suggested that Fe65 could have some nuclear functions, considering its presence in 
the nucleus and its interaction with several nuclear proteins. These results supported the 
hypothesis that Fe65 could be involved in the regulation of transcription, although most of 
them rely on the use of reporter gene assays. Fe65 appears to function as a key regulator of 
signals received and integrated at the membrane by APP holoprotein which modulates 
Fe65 nuclear localization and functions. Starting from the observation that the absence of 
Fe65 results in vivo and in vitro in high vulnerability to DNA damaging agents we tried to 
understand the molecular mechanism involving Fe65 and the Fe65/APP complex in this 
new biological function. We found for the first time that Fe65 is a chromatin bound protein 
that modulates the degree of chromatin condensation and is necessary for Tip60 proper 
function during DNA repair. Indeed the knockdown of Fe65 provokes a significant 
decrease in the recruitment of Tip60 and TRRAP to DNA double strand breaks. 
Accordingly, Fe65 suppression also provokes a dramatic decrease of histone H4 
acetylation of lesioned chromatin and, in turn, the impairment of DNA repair efficiency. 
Furthermore, we demonstrated that the interaction of Fe65 with APP is necessary to allow 
Fe65 to associate with chromatin and therefore to play its role in the response to DNA 
damage. Based on these results we propose the hypothesis that Fe65 and its interaction 
with APP play a crucial role in the association of the NuA4 complex containing Tip60 and 
TRRAP to DNA lesion. Although further studies are necessary to definitively address the 
mechanisms of the Fe65 involvement in DNA repair and chromatin remodeling, available 
knowledge allow us to propose the model reported in Figure 34. The first step of this 
model is the interaction of Fe65 with APP. Our results demonstrate that a Fe65 mutant  
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Available results support the hypothesis that Fe65 exists in two conformations. The 
interaction with the cytodomain of APP induces Fe65 from a “close” (a) to an “open” (b) 
conformation. The cleavage of APP or its phosphorylation may cause the release of Fe65 
from the membrane anchor (c) thus allowing its association with chromatin (d). In basal 
conditions, chromatinized Fe65 appears to have a general role in favoring chromatin 
condensation. Chromatin associated Fe65 is necessary for the recruitment of Tip60-
TRRAP-containing complex at DNA double strand breaks (e). Loss of function of the 
Fe65-APP machinery induces a significant decrease of DNA repair efficiency. 
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unable to interact with APP fails to rescue the phenotype induced by Fe65 KO. Moreover, 
the same mutant has a clear dominant negative effect on the recruitment of Tip60-TRRAP 
at the DNA lesion and, in turn, on the DNA repair efficiency of the cells (see figure 34). 
One possible explanation of the loss of function of the C655F mutant could be based on the 
model proposed by Cao and Sudhof (Cao and Sudhof 2004). This model suggests that the 
interaction of Fe65 with APP induces a conformational change leading Fe65 from a 
“closed” to an “open” conformation. The “closed” conformation could be due to an 
intramolecular interaction between the WW domain-containing region and the PTB 
domain region (Cao and Sudhof 2004). The APP cytodomain opens this structure by 
competing for the binding of the WW domain with the PTB2. A Fe65 deletion mutant, 
lacking the entire PTB2 domain, is, similarly to the C655F mutant, completely unable to 
interact with APP. However, this mutant protein, rescues the phenotype of Fe65 KO cells 
(data not shown). On this basis it could be speculated that this ΔPTB2 mutant is in a 
constitutive “open” conformation, thus rescuing the absence of Fe65. On the contrary, the 
C655F mutant could be in a constitutive “closed” conformation, therefore being unable to 
rescue the effects of Fe65 suppression. The loss of the function of this C655F mutant is 
likely due to the fact that, opposite to what observed with wild type Fe65, it is unable to 
interact with the chromatin, while it is still able to interact with Tip60 (see figure 30), thus 
explaining why it exerts a strong dominant negative effect. Further evidence supporting the 
involvement of APP in the nuclear function of Fe65 comes from the results showing that 
the suppression of APP/APLP2 leads to the impairment of Fe65 functions. In fact, in 
APP/APLP2 KD cells the association of Fe65 to chromatin is strongly reduced and 
accordingly the recruitment of Tip60-TRRAP to damaged DNA, histone H4 acetylation 
and DNA damage repair are decreased. The second step of our model is the translocation 
of “active” Fe65 from its APP anchor site to the chromatin. One possible mechanism for 
this event implies the proteolytic processing of APP followed by the release of AICD-Fe65 
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from the membrane. This possibility is supported by the induction of γ-secretase cleavage 
observed in response to DNA damaging agents (see figure 26). Another possibility is that 
post-translational modifications of APP and/or Fe65 cause the release of Fe65 and its 
nuclear translocation. For example, the phosphorylation of Thr668 of APP is an interesting 
candidate as a trigger mechanism inducing the release of Fe65 (Ando, Iijima et al. 2001). 
Our results indicate that, in basal conditions, nuclear Fe65 is associated to chromatin. As 
mentioned before, this association requires the interaction with APP, because a mutant 
Fe65 unable to interact with APP is not associated to chromatin and APP/APLP2 
suppression decreases the association to chromatin of endogenous Fe65. The Fe65 KO or 
KD leads to a decondensation of the chromatin structure, therefore, at least in basal 
conditions, Fe65 seems to favor a condensed state of the chromatin. This Fe65 function 
remains to be studied in details. However, it seems to be distinct from that involved in the 
response of the cells to DNA damage and in the repair of the lesions. Chromatin fiber 
decompaction could be dependent at least in part on histone H4 acetylation, likely 
catalyzed by Tip60 (Shogren-Knaak, Ishii et al. 2006), thus Fe65 could also negatively 
regulate, via its interaction with Tip60, global histone acetylation and in turn the chromatin 
state. However, it is not expected that the phenotype observed in Fe65 KD cells, i.e. 
reduced efficiency of DNA repair, is a consequence of chromatin decompaction, 
considering that, at least in principle, decompacted chromatin should favor and not hamper 
DNA repair. This paradox could be explained by hypothesizing that Fe65 has two related 
but distinct effects on chromatin: on intact chromatin Fe65 favors the compaction of the 
chromatin, while, upon DNA double strand break, it stimulates the recruitment of Tip60, 
the acetylation of histone H4 and in turn the local relaxation of the chromatin. This 
possibility is reasonable if we consider that Fe65 is an adaptor molecule, which can 
interact with several different ligands. The ΔPTB1 mutant has also a strong dominant 
negative effect. This dominant effect is in part due to the fact the this mutant was found 
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associated with chromatin (see figure 22) and could be the consequence of the titration of 
some other partners of Fe65, which may be necessary for the proper function of Fe65. 
Among these Fe65 partners, possibly involved in the phenomena we have described, there 
are the Set protein and the Abl tyrosine kinase. Both of them interact with the WW domain 
of Fe65 (Telese, Bruni et al. 2005) (Zambrano, Bruni et al. 2001) and could be involved in 
the nuclear functions of Fe65. Set is, in fact, a component of the INHAT complex 
(inhibitor of histone acetyl transferase) (Seo, McNamara et al. 2001) and nuclear Abl has a 
well-known role in the cellular response to DNA damage (Kharbanda, Ren et al. 1995). 
The third step concerns with the mechanisms through which Fe65 favors the recruitment of 
Tip60-TRRAP to the damaged DNA. Since Fe65 is associated to chromatin in basal 
conditions, one hypothesis is that Tip60-TRRAP containing complex is recruited to DNA 
lesion by binding Fe65 that is already on the chromatin. This hypothesis implies a signal 
inducing the interaction between Fe65 and Tip60- TRRAP. This signal could be the 
phosphorylation of Fe65, which was demonstrated to take place few minutes after the 
genotoxic stress (see figure 12). However, it cannot be definitively excluded that Fe65 
suppression is affecting repair events upstream of the recruitment of Tip60-TRRAP, 
considering that Tip60 is involved in many different steps of DNA repair, either dependent 
or independent from NuA4 (Squatrito, Gorrini et al. 2006). For example, it is known that 
Tip60 associates with and acetylates ATM, thus promoting its activation (Sun, Jiang et al. 
2005). The possibility that Fe65 suppression alters these events seems to be excluded by 
the finding that Fe65 KO does not affect ATM activation upon DNA damage (figure 10). 
The study of APP has tried to address the possible role of dysfunction of this molecule in 
the pathogenesis of AD. Our results suggest that the involvement of the Fe65-APP 
complex in the response of the cells to DNA damage and in the DNA repair machinery 
should be taken into account as a possible mechanism contributing to neuronal dysfunction 
observed in AD pathology.  
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In the Fe65; Fe65L1 double KO mice the phenotype observed (Guenette, Chang et al. 
2006), mainly characterized by focal heterotopias of neurons likely due to the pial 
basement membrane disruption and intriguingly similar to that observed in APP; APLP1; 
APLP2 mice (Herms, Anliker et al. 2004), is very likely due to the impairment of an 
unknown Fe65 function different from that responsible for the phenotype we are 
describing. However, it should be considered that numerous human genetic diseases due to 
mutations of the DNA damage response machinery are also characterized by marked 
neurological defects (Rolig and McKinnon 2000). This close association has been 
interpreted either by hypothesizing a particular sensitivity of the neuronal cells to DNA 
damage or to the possibility that proteins involved in the response to DNA damage and cell 
cycle control also have additional and distinct functions in neurons. There are several 
observations that suggest exploring whether an altered processing of APP, and in turn a 
modification of its functions, could negatively affect the response of the neurons to DNA 
damage in AD brain, thus leading to chronic accumulation of DNA damages that could 
significantly contribute to the neuronal loss characteristics of AD pathology. In agreement 
with this possibility, it was reported that AD brains show high incidence of nuclei 
containing DNA strand breaks (Adamec, Vonsattel et al. 1999) and fibroblasts and 
lymphocytes from AD patients, exposed to DNA damaging agents, show more DNA strand 
breaks than the cells from normal subjects (Parshad, Sanford et al. 1996). Numerous results 
indicate that the neurotoxic effects of Aβ could be dependent on its prooxidant activity 
(Reddy 2006), which could favour oxidative DNA damage. An altered response of neurons 
to DNA damage in AD is also suggested by the reexpression of cell cycle proteins 
observed in AD brain (Herrup, Neve et al. 2004). This reexpression occurs long time 
before the death of the neuron, thus it is hard to be considered part of a suicide mechanism 
to eliminate damaged cells. On the contrary, it could represent part of a mechanism to 
protect the cell by favoring the repair of DNA damages, also considering that cell cycle 
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reentry also occurs in neurons treated with DNA damaging agents (Kruman, Wersto et al. 
2004). This possibility deserves further attention, also considering that numerous studies 
have pointed to the accumulation of DNA lesions, including double strand breaks mostly 
due to oxidative damage, in mild cognitive impairment and in AD. These observations 
indicate that DNA damage occurs in all the steps of the disease progression and DNA 
repair defects could significantly contribute to neurodysfunction and neurodegeneration 
observed in dementia (Lovell and Markesbery 2007). This hypothesis is in agreement with 
a new model proposed for Alzheimer disease pathogenesis. Indeed despite the unsolved 
questions linked to the “amyloid hypothesis”, emerging hypothesis such as the “dual 
pathways model” (Figure 35) (Small and Duff 2008) seems to better explain the 
relationship between Aβ and tau abnormalities in Alzheimer disease. The ‘‘amyloid 
hypothesis’’ suggests a serial model of causality in which abnormal tau phosphorylation is 
a secondary disfunction due to the accumulation of Aβ that leads to synaptic loss and 
neuronal death. The weakness of this hypothesis is mainly unmasked by the observation 
that although the lowering of Aβ was achieved during anti-Aβ immunotherapy trials, tau 
pathology, neuronal loss and cognitive impairment were still present in immunized AD 
patients. On the other hand the “dual pathways model” links the elevations of Aβ peptide 
and tau hyperphosphorylation through common upstream molecular defects implicated in 
Alzheimer’s disease. Although many question remain to be addressed and many efforts are 
needed to demonstrate the causative role of DNA damage defects in Alzheimer disease 
neurodegeneration, our results open the possibility to explore the involvement of DNA 


































The amyloid hypothesis assumes a serial model of causality, whereby abnormal elevations 
in Aβ drive tau hyperphosphorylation and other downstream manifestations of the disease. 
According to the dual pathway hypothesis, Aβ elevations and tau hyperphosphorylation 
can be linked by separate mechanisms driven by a common upstream molecular defect 
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